Introduction
Proper clinical studies (clinical trials) are essential to introduce new therapeutic drugs, including antibacterial drugs. It is extremely important for the welfare of people that clinical studies are conducted in a reliable and smooth manner.
The Japanese Society of Chemotherapy established the "Clinical Trial Committee", "Consent Document Preparation Committee", "Protocol Composition Committee (Respiratory Tract, Urology)" and "Bridging Study Review Committee" to establish standards necessary for upgrading the level of clinical studies.
The Protocol Composition Committee (Respiratory Tract) has prepared the drafts of the standard study protocol and Case Report Form (CRF) as herein published.
This protocol draft has been prepared in compliance with "Guidelines for the Clinical Evaluation of Antimicrobial Drugs" prepared by the committee in 1998 basically in every detail, and also in compliance with "General Guidelines for Clinical Studies" (Notification No. 380 of the Evaluation and Licensing Division, PMSB, April 21, 1998) and "Guidelines for the Clinical Evaluation of Antimicrobial Drugs" (Notification No. 743 of the Evaluation and Licensing Division, PMSB, August 25, 1998) in every possible details.
The protocol and CRF drafts will be finalized as the society's standards in one year after the publication. Parties concerned are invited to give forthright opinions in writing to the secretariat of the society.
Without a great deal of cooperation of the staffs of the pharmaceutical manufacturers currently engaged in the development of new antimicrobial drugs, it would have been impossible to prepare the protocol and CRF drafts, and we would like to acknowledge their contribution.
I Introduction: The Philosophy and Fundamental Attitudes of the Committee
The underlying philosophy and the role of clinical trial protocols
In preparing this protocol, every effort has been made to use plain expressions so that principal investigators and all other people who will be involved in a clinical trial can read the protocol, understand its contents, and conduct the trial. In addition, this protocol has been prepared so that the ethical and scientific validity of clinical trials can be clearly presented to third parties. In order to develop pharmaceutical products efficiently, the sponsor of a clinical trial must prepare a protocol that is easy to understand by fully utilizing this protocol as a reference.
(1) Assuring the safety and protection of the human rights of subjects The safety of subjects must be fully assured with respect to the investigational product. It is also important to protect the privacy of subjects in regard to information obtained in the course of the clinical trial. This matter is an aspect of the protection of human rights. We have therefore decided to specify in this protocol rules for the assurance of safety because such rules are important from the viewpoints of safety and human rights. (2) Assuring the reliability of the evaluation of the investigational product A clinical trial protocol must include the contents that are stipulated in the following documents. GCP based on the Guideline for Good Clinical Practice by the ICH Steering Committee (Guideline for Good Clinical . Every effort has been made to document evaluation methods clearly and in detail, in order to eliminate differences in interpretation by each investigator, to make it possible to conduct uniform trials and evaluate investigational products correctly, and to verify the scientific and ethical validity of the evaluation methods. The ethical and scientific validity of data collection and data evaluation methods must be presented to the institutional review boards and regulatory authorities. We have therefore clearly documented the validity of the settings in this protocol. (4) Increase the efficiency of the development of investigational products It is generally considered that a protocol that is prepared on a scientific basis decreases differences in interpretation among clinical trial sites and evaluators. It adds consistency to evaluation outcomes, and as such, increases the reliability of the clinical trial. Establishing the appropriate subject population and duration of the trial will increase the efficiency of the development of investigational products and minimize the level of exposure of subjects to new substances and the effects of the research-aspect of the trial; thus protecting the wellbeing of subjects. Therefore, in preparing this protocol we have paid great attention to establishing the scientific basis of the protocol by marshaling various scientific sources.
Fundamental attitude toward the preparation of the clinical trial protocol
Attempts have been made to standardize clinical trial procedures. Research on Standardization of the Use of Antimicrobial Agents was released in 1982 and amended in 1987. Guidelines for Clinical Evaluations of Antimicrobial Agents was released by Japanese Society of Chemotherapy in 1998. GCP was amended in 1997 (New GCP) and Good Clinical Trial Protocol was produced by Japan Pharmaceutical Manufactures Association in 1999. Drugs that are newly developed are different from each other in regard to type, antimicrobial activity, degree of absorption and elimination, metabolism, administration route, and indications to be treated. It is impossible to prepare one protocol that can be applied equally to all developmental drugs.
We have therefore described the important issues for each type of antimicrobial agent and each phase of a trial. Then, on the basis of these points, we have prepared and presented a protocol that illustrates the fundamental structure that is common to all trials for antimicrobial agents. Figure 1 illustrates the structure of clinical trials.
Establishing clinical evaluation methods, variables to be assessed (endpoints) and duration of the observation of progress
Based on Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (1997, Japanese Society of Chemotherapy), the disease categories for clinical evaluation of respiratory tract infections are acute upper respiratory tract infections, secondary infection of chronic respiratory illness, and pneumonia. In accordance with the same document, there are two categories for the assessment of the efficacy of the investigational product; they are clinical efficacy assessment and microbiological efficacy assessment. Objective criteria will be established for clinical efficacy assessment, and will be evaluated as "effective" or "ineffective". Microbiological efficacy assessment will be conducted in accordance with General Guidelines for Clinical Evaluation of Antimicrobial Agents, 1996. The safety of the investigational product will be evaluated in terms of subjective and objective adverse drug reactions, as well as abnormal laboratory test values. Safety will be assessed in accordance with General Guidelines for the Clinical Evaluation of Antimicrobial Agents, 1996, and Assessment Criteria for Adverse Drug Reactions and Abnormal Changes in Laboratory Parameters in Clinical Trials for Antimicrobial Agents (Chemotherapy 39:687, 1991; and Jpn. Chemother.43 (11), 1995, Amendment).
Efficacy (clinical and microbiological) and safety evaluations will be assessed comprehensively in order to determine an overall assessment. The importance of each variable will depend on the characteristics of the investigational product. The criteria for assessment must therefore be specified in the protocol.
By convention, each variable for overall assessment is assessed at the end of treatment (EOT). However, the current international trend is to conduct assessment at the end of the study (EOS).
Therefore, the timing of the evaluation of each variable of acute upper respiratory tract infections and pneumonia is set at: three days following the commencement of administration, the day following the completion of administration, and 7-10 days following the completion of administration. The timing of evaluation of each variable of secondary infection of chronic respiratory illness is set at: three days following the commencement of administration, the day following the completion of administration, and 7-21 days following the completion of administration.
Efficacy/safety variables (endpoints) and the timing of evaluations vary in accordance with the characteristics of the investigational product. Therefore, it is necessary to designate variables as either primary efficacy/safety variables (primary endpoints) or secondary efficacy/safety variables (secondary endpoints). It is also necessary to clearly document this division in the protocol. For example, primary endpoint: Clinical efficacy at 7-10 days following the completion of administration; secondary endpoints: Clinical efficacy on the day following the completion of administration, and microbiological efficacy at 7-10 days following the completion of administration. It is possible to choose multiple endpoints.
The observation of progress period must be long enough to allow for follow-up, which may be deemed necessary for safety reasons. The decision to conduct follow-up will be based on the results of the overall assessment. The observation of progress period must be set in advance and from the viewpoints of drug safety and ethics. The end of the observation period is the end of the study.
Fundamental attitudes in regard to assuring the quality of clinical trials
The quality of all clinical trials must be high and it must be assured. In order to comply with these requirements, the sponsor must carefully select clinical trial sites and investigators on the basis of thorough surveys and examinations of the items described below. In addition, the sponsor must describe the following items in detail in the protocol in order to assure the quality of the trial. The sponsor must instruct all investigators to comply with the protocol.
4-1 Clinical trial sites
In order to enhance and assure the quality of the trial, all trial procedures conducted at trial sites must comply with the New GCP. In fact, each trial site must have its own regulations in regard to conducting clinical trials (standard operating procedures), as well as institutional review board (IRB) operating procedures. The IRB must comply with the New GCP in regard to the number and requirements of board members. In addition, the medical institution must have a well-established system of precautions and emergency procedures (e.g. an established method of communication in case of an onset of serious adverse events). Therefore, it is desirable for trial sites to have their own clinical trial administrative office with designated investigator(s) and an adequate number of clinical research coordinators (CRC), commensurate with the trial.
4-2 Investigators
Principal investigators and subinvestigators play an important role in clinical trials. In particular, principal investigators are responsible for the quality of the clinical trial, which is of utmost importance. Therefore, prior to selection of principal investigators, it is necessary to conduct the investigations described below.
The principal investigators are required to have a high level of medical knowledge in the area of the target of the clinical trial. The sponsor should select principal investigators on the basis of the following credentials: Accredited infection control doctor (ICD), a doctor who is accredited by The Japanese Society of Clinical Pharmacology and Therapeutics, a doctor who is registered by Japanese Society of Chemotherapy as an instructor of clinical trials for antimicrobial agents, membership of various of infectious disease-related societies, the number of years experience in the target field, the number of years experience as an investigator, and the amount of time that candidates have available for carrying out the trial.
4-3 Clinical trial protocol
The protocol must describe in the sections listed below, clearly and in detail, the means by which the quality of the trial will be improved, maintained and assured. The aspects of quality that must be addressed are in respect to the subjects, the trial sites, the investigators, and the sponsor. The trial must then comply with these descriptions. The sections are "Compliance with GCP", "Indications studied and inclusion/exclusion criteria", "Consent obtainment from and information supply to subject", "Compliance with the protocol", "Documentation of the case report form", "Acceptance of direct access to source data/ documents", "Acceptance of monitoring for quality control and quality assurance of the clinical trial" and "Record storage".
The necessity of late phase II clinical trials
Late phase II clinical trials were conventionally conducted to verify the appropriateness of dosages that were estimated on the basis of the results of pre-clinical studies and phase I clinical trials. They were also conducted to explore the recommended clinical dosages for double-blind studies in phase III clinical trials. However, the opposite results for clinical efficacy were often observed between high-dose and low-dose groups because an insufficient number of cases were studied.
From these circumstances, there is a growing belief that it is suitable to explore the appropriate dosage in non-clinical studies, phase I clinical trials, un-blind studies in phase II clinical trials, and un-blind studies in phase III clinical trials. Furthermore, as late phase II clinical trials are usually not conducted in Western countries, it is not necessary to conduct late phase II clinical trials if the appropriate dosage can be determined from other phases of the trial.
Control drugs in controlled studies
Comparison with other drugs: Control drugs were selected from drugs in the same category as the investigational product and for which the results of clinical evaluation have already been established. However, control drugs will henceforth not need to be in the same category as the investigational product, and they may be any currently available drugs. It is possible to conduct controlled studies with control drugs of a different category as long as the basis for the selection of the control drugs is specified. In such cases, it is important to consider what types of characteristics constitute the most suitable control drug in order to clarify the superior characteristics of the investigational product.
Controlled studies with concomitant drugs: Previously, controlled studies conventionally referred to a comparative study involving the investigational product and another drug. However, if the antimicrobial agent that is being developed is expected to be frequently used in conjunction with a certain drug, or if synergy between the investigational product and a concomitant drug is anticipated, it is desirable to conduct controlled studies with the concomitant drug.
The severity of the diseases of subjects and evaluation methods
Previously, a subject could participate in trials only if his/ her disease was either mild or moderate. However, it is possible to include subjects with severe diseases in accordance with the characteristics of antimicrobial agents. In such cases, it is necessary to clarify (in the severity criteria) the distinction between infectious diseases and underlying diseases. In addition, it is necessary to establish new clinical evaluation methods for each disease. For example, you may select the prognosis of subjects following the commencement of the clinical trial, or the improvement in the quality of life (QOL) as the primary efficacy variable (primary endpoint), or secondary efficacy variable (secondary endpoint). Variables are not necessarily limited to clinical efficacy and microbiological efficacy.
These points must be fully documented in the protocol.
Clinical trials in accordance with clinical pathologic classifications of respiratory tract infections
Pneumonia can be classified into many different clinical pathological categories (e.g. Community acquired pneumonia, nosocomial pneumonia, ventilator associated pneumonia (VAP), pneumonia without an underlying disease, and nursing home acquired pneumonia). This also applies to secondary infection of chronic respiratory illness. It is possible to design a clinical trial in which the characteristics of the antimicrobial agent being developed are verified on the basis of the efficacy of each pathological classification of infectious disease. In this case, the protocol will be very different from that presented in this paper. Ensure that the protocol is prepared by fully considering the fundamental attitudes described in this paper.
Cases in which a small dose of macrolide has been administered over a long period
There are many cases in which a small dose of macrolide (e.g. erythromycin) has been administered over a long period in order to control a chronic respiratory illness such as diffuse panbronchiolitis (DPB). We think that the usefulness of this treatment has been proven.
In the past, some treatments have been discontinued in order to conduct clinical trials, although in actual clinical situations treatments are not discontinued simply to administer antimicrobial agents that have been recently released on the market. We do not think it is necessary to discontinue long-term administrations for clinical trials, except in cases where the administered drug is thought to significantly influence the evaluation of the investigational product if used in conjunction with the investigational product.
Establishment of diagnostic criteria
Although it is very rare to identify the pathogenic bacteria for respiratory tract infections, considerable effort should be given to a diagnosis on the basis of microbiological findings. If bacteria are isolated, it is comparatively easy to diagnose the disease. However, it is difficult to isolate viruses, mycoplasmas, chlamydias and legionellas in order to culture them. Therefore, serum antibody titer measurements, antigen detection or gene examinations are often carried out in order to diagnose diseases. In these cases, it is necessary to fully consider the circumstances and possible outcomes, prior to the commencement of the trial, and determine the test method(s) and diagnostic criteria in advance.
Necessity of intracutaneous test in the development of injections
Intracutaneous tests that are conducted in clinical trials for antimicrobial agents (primary -lactam antimicrobial agents) are not regarded as useful for predicting the risks of anaphylactic shock and other allergic reactions. Indeed, the tests are not conducted in any western countries. Although our committee sees intracutaneous tests as not necessary, we have a history of conducting them in Japan. It is necessary to be aware that we will collect evidence to support the abolishment of the tests in the future.
When conducting the clinical trial, it is necessary to be fully aware of the risk of the onset of allergic reactions, including shock, due to the investigational product. It is necessary to prepare readily available measures and response for such cases.
Other considerations
The following topics will be discussed in each designated section: The basic principles of each phase of a clinical trial (early phase I, late phase II, phase III and phase IV); criteria for each disease (acute upper respiratory tract infections, secondary infection of chronic respiratory illness and pneumonia); and important points for each type of antimicrobial agent ( -lactam antimicrobial agents, macrolides, quinolones, new antimicrobial agents, oral drugs and injections). laryngitis are included in this category. However, acute rhinitis, acute sinusitis and acute tympanitis are usually treated in otorhinology departments and are therefore not included here. -streptococcus is the most common pathogenic bacteria of acute tonsillitis and peritonsillar abscess, followed by pneumococcus, Staphylococcus aureus and Haemophilus influenzae. In most cases, the pathogenic microorganisms of acute pharyngitis and acute laryngitis are viruses. If these viruses damage the mucous membranes of the respiratory tract, secondary infections occur in that area. The most common pathogenic bacteria of secondary infections are Streptococcus pyogenes, followed by pneumococcus, Staphylococcus aureus and Haemophilus influenzae.
Acute upper respiratory tract infections that may be studied for the purposes of developing oral antimicrobial agents to be used in the field of internal medicine are acute tonsillitis and acute bacterial pharyngitis/laryngitis. Acute upper respiratory tract infections, which may be studied for the purposes of developing antimicrobial injections to be used in the field of internal medicine, are peritonsillar abscess and retropharyngeal abscess.
Outline of acute lower respiratory tract infection (acute bronchitis)
Acute lower respiratory tract infection is acute bronchitis. In general, bronchitis occurs because the upper respiratory
II Outline of Respiratory Tract Infectious Diseases and Indications Studied in Clinical Trials
Respiratory tract infections can be divided into three groups in accordance with the infected area: Respiratory tract (upper and lower), lung (parenchyma and interstitium), and pleura. From the viewpoint of clinical trials for antimicrobial agents, diseases that develop in these parts include upper respiratory tract infections (acute), lower respiratory tract infections (acute and chronic), pneumonia, pulmonary suppuration, and acute purulent pleurisy. Of these, pneumonia and chronic lower respiratory tract infection (secondary infection of chronic respiratory illness) are the most important diseases.
The following are brief descriptions of each disease.
I. Acute respiratory tract infection
Outline of acute upper respiratory tract infection
Acute upper respiratory tract infection is a general term for any acute infections that develop in the upper respiratory organs, including the nose, mouth and glottis. Another name is common cold syndrome. Acute rhinitis, acute sinusitis, acute tympanitis, acute tonsillitis, peritonsillar abscess, acute pharyngitis, retropharyngeal abscess and acute 1) The name of each indication is followed by their pathogenic bacteria names (e.g. tonsillitis due to Staphylococcus aureus, pneumonia due to Streptococcus pneumoniae), with the exception of Streptococcal pharyngitis/tonsillitis. 2) In Japan, there is no uniform system of classification, and usage has been changing over time. As this may create confusion in clinical situations, our society has suggested to the Ministry of Health, Labor and Welfare to unite classifications as follows (as of 2000). a. Acute bronchitis includes bronchitis and acute bronchitis. b. Currently, all infectious bacterial diseases that develop in addition to a chronic respiratory illness are described as "secondary infection of chronic respiratory illness". Examples include acute exacerbation of chronic bronchitis, bronchiectasis ϩ infection, bronchial asthma ϩ infection, pulmonary emphysema ϩ infection, pneumoconiosis ϩ infection, inveterate tuberculosis ϩ infection, and interstitial pneumonia ϩ infection. c. All bacterial pneumonia, with the exception of atypical pneumonia, are described as pneumonia. This is the same as conventional categorization. If the indication is pneumonia due to mycoplasma, chlamydia, legionella, Methicillin-resistant Staphylococcus aureus (MRSA), the name is described as "pneumonia (including XXXX pneumonia)". d. Conventional pulmonary abscess and pulmonary gangrene are described as pulmonary suppuration. e. Conventional thoracic empyema and pleurisy are described as thoracic empyema.
tract infection spreads to other areas along the airway. Therefore, the pathogenic microorganisms of this disease are mainly the same as those in upper respiratory tract infections. However, the lower respiratory tract is more susceptible to primary and secondary bacterial infections than is the upper respiratory tract. The most common pathogenic bacteria of acute bronchitis are Haemophilus influenzae, followed by pneumococcus and Moraxella catarrhalis.
In epidemic seasons, mycoplasmas are often the pathogenic microorganisms of acute upper/lower respiratory tract infections, as is Chlamydia pneumoniae. However, the symptoms and findings of the inflammation caused by these pathogenic microorganisms may remain mild. In addition, the antimicrobial agents that are effective against these microorganisms are different from the agents that are effective against the bacteria mentioned above. We therefore established different criteria for cases in which bronchitis is due to these microorganisms.
Pathological classifications of acute upper/lower respiratory tract infections studied in clinical trials
Indications to be studied for antimicrobial agents are generally bacterial infections. Therefore, secondary bacterial infections that occur in the upper/lower respiratory tract after temporary viral infections are valid indications.
The indications studied in clinical trials of acute respiratory infections are infections due to bacteria, not viruses. For example, fever, pharyngeal pain, cough and sputum are observed in both viral and bacterial infections, but icteric sputum, leukocytosis, skeocytosis and neutrophilia are observed only in bacterial infections. Cases in which these symptoms/findings are observed are eligible to be subjects in clinical trials.
Acute respiratory tract infections are usually mild to moderate. It is very rare that these infections are categorized as severe. Therefore, patients with such infections are usually outpatients, and only oral antimicrobial agents are used in drug therapy.
We exclude acute respiratory tract infections that has developed in patients with chronic respiratory illness from this category, as it should be regarded as a secondary infection of a chronic respiratory illness.
Trial-subject criteria for cases with acute bacterial upper/lower respiratory tract infections
Cases are eligible to be subjects in clinical trials if the symptoms and findings of upper/lower respiratory tract infections are observed, and they satisfy (1) and at least two of the other four criteria ((2), (3), (4) or (5)).
(1) Bacteria that are suspected as pathogenic microorganisms have been detected in a specimen such as sputum, or are likely to be detected, or a good specimen has been obtained (e.g. a specimen that includes plug of pus, purulent secretion or purulent sputum), even though pathogenic microorganisms have not been detected.
(2) Leukocytes м8000/mm 3 (3) Rod neutrophils м10% (4) CRP м0.7 mg/dl (or CRP exceeds the upper limit of the relevant institute) (5) Body temperature м37.0°C
Trial-subject criteria for cases with infections due to mycoplasma or chlamydia
Cases are eligible to be subjects in clinical trials if the symptoms and findings of upper/lower respiratory tract infections are observed and they satisfy any of the categories in (1) , and at least three of the other six criteria ((2), (3), (4), (5), (6) or (7) 
Outline of diseases
Pneumonia is an acute lung parenchyma infection due to various microorganisms. It is the primary disease of respiratory tract infections. Pathogenic microorganisms include general bacteria, atypical microorganisms (mycoplasmas, chlamydias and legionellas), viruses, acid-fast bacteria, fungi and protozoa. The indications to be studied in clinical trials to develop antimicrobial agents are pneumonia due to general bacteria and pneumonia due to atypical microorganisms. Pneumonia due to other microorganisms should be evaluated and assessed on the basis of criteria established in accordance with the characteristics of each microorganism.
If the pathogenic microorganisms are suspected to be bacteria, sputum discharged from the mouth is usually tested to obtain confirmation. It is somsetimes difficult to obtain sputum in cases of pneumonia, and it may therefore be necessary to take measures such as forced expectoration by means of gargling or a strong cough, guided expectoration by means of nebulizer, tapping or postural drainage. If these measures do not work, use a throat swab or nasopharynx scraping as a substitute. If a high fever is observed shortly after the patient develops the infection, it is desirable to conduct blood culturing without limiting the bacteria type because the patient is possibly suffering bacteremia.
Ideally, the pathogenic microorganisms can be identified so that only appropriate cases are included in clinical trials and the clinical efficacy of the investigational antimicrobial agent can be evaluated correctly. However, in actual clinical situations, we cannot avoid commencing antimicrobial drug therapy without knowing the pathogenic microorganism. As such, the probable pathogenic bacteria must be inferred from the subject's background. The basis of inclusion in the clinical trial will be consideration of the antimicrobial activity of the investigational product, the pharmacokinetics of the investigational product (distribution to lungs), and adverse drug reactions due to the investigational product. If it is decided that the case will be included, an appropriate dosage will be determined by calculating the concentration of the drug in the lesion (lesion size is determined by the results of chest X-rays).
Pneumonia is roughly divided into two groups: community acquired pneumonia and nosocomial pneumonia. Community acquired pneumonia occurs in people who live in a community outside the hospital. Pneumonia with a mild underlying disease/complication(s) is included in community acquired pneumonia. However, if patients are elderly and have low ADL, they must be excluded from some phases of the clinical trial, even if their disease is community acquired pneumonia. If a certain level of organic changes are observed in the tract and alveoli, the changes cause infections repeatedly, and there is clear evidence of a respiratory tract infection over a wide area, the patient must be diagnosed with a respiratory tract infection, even if their chest X-rays display a certain spread of shading (alveolitis). A key issue in the diagnosis of community acquired pneumonia is that the patient lived in a community outside the hospital when they developed pneumonia. They may or may not have a mild underlying disease/complication(s). By contrast, nosocomial pneumonia occurs in people who are hospitalized. In general, pneumonia that develops within 48 hours of hospitalization is called nosocomial pneumonia. This type of pneumonia develops from a disease that a patient had at the time of hospitalization. The pathogenic microorganisms of nosocomial pneumonia may be microbiologically very specific because they develop in a specific environment, i.e. within hospitals.
As we described in the section on acute respiratory tract infections, mycoplasmas are often detected as pathogenic microorganism of pneumonia during epidemic seasons. In addition, the number of cases in which Chlamydia pneumoniae is the pathogenic microorganism of pneumonia increases in such a season. If they are pathogenic microorganisms, the symptoms and findings of inflammation remain mild in many cases. In addition, the antimicrobial agents that are effective against these microorganisms are different from those that are effective against other bacteria. We have therefore established different criteria for cases of pneumonia due to these microorganisms.
Plain chest X-rays are usually used to examine shading in the lungs. i) In order to observe shading accurately, it is desirable to use conventional methods. The use of computed radiography (CR) should be avoided if possible, as exudation (the most fundamental sign of inflammation) is not fully projected in these images if the intensity of exudation does not exceed a minimum level.
In some cases it is best to conduct computed tomography (CT) because CT indicates exudation more clearly than conventional plain X-rays or CR images. If shading is observed in CT images, use the CT images primarily to evaluate shading and calculate the score. In order to reach a final score, add up all shaded areas, and then consider the shading of plain conventional X-rays or CR images. (As a scoring method for CT images has yet to be established, conventional scoring methods must be used with some adaptation until this is achieved.)
ii) Chest images are usually taken from the anterior perspective and it is therefore easy to recognize the spread of shading in the left/right and up/down dimensions. However, it is difficult to see the depth of spreading (e.g. whether shading has spread to the sub-segment such as S3b or not). It is necessary to take lateral images if the depth of spread needs to be examined.
iii) The intensity of shading depends on the intensity of exudation (the most fundamental sign of inflammation). If shading is extremely dark, an extra point is added to the score in the rating the expansion of pneumonia. Reduction in the density of shading following administration of antimicrobial agents must be evaluated accordingly.
Disease level of subjects who are eligible to participate in clinical trials
The severity of an infectious disease is an extremely important criterion in determining whether a patient can be included in clinical trials for antimicrobial agents. The severity of the underlying disease/complication(s) is also important. The seriousness of a patient's condition is determined by comprehensively assessing the severity of the two aforementioned conditions.
If the investigational antimicrobial agent is an oral drug, patients who are eligible to be subjects are primarily outpatients in which the severity of the infectious disease is moderate or less than moderate, and with a mild underlying disease/complication(s) (if any).
By contrast, if the investigational antimicrobial agent is an injection, only inpatients may become subjects. In the past, the severity of an infectious disease in a patient who was eligible to participate in clinical trials was moderate or less; however, it is now possible to include patients with severe infectious diseases in trials (depending on the characteristics of the investigational product).
A patient with a severe underlying disease/complication(s) is categorized as serious in the classification of the seriousness of a patient's condition, even if the severity of the infectious disease is mild. Considerable caution is required in clinically evaluating the investigational antimicro-bial agent from test results obtained from these patients. In addition, a different protocol needs to be prepared for evaluation.
Trial-subject criteria for cases with pneumonia
Cases are eligible to be subjects in clinical trials if the symptoms and findings of pneumonia are observed, and if they satisfy the following criteria.
(1) Chest X-rays or CT images project a newly developed shadow. (2) Acute inflammatory findings such as neutrophilia, skeocytosis (rod neutrophils м10%), an increase in CRP (1.0 mg/dl or more) and an increase in ESR are observed in hematological tests.
Both the above criteria and at least two of the following four criteria must be satisfied.
(3) Fever (Ͼ37°C) (4) Respiratory system-related symptoms such as cough, sputum (purulent sputum), chest pain and breathing difficulty (5) Moist rale (6) Microorganisms that are suspected to be pathogenic microorganisms were detected from specimens such as sputum, or a good specimen that is likely to contain pathogenic microorganisms can be obtained.
Trial-subject criteria for cases with Mycoplasma(M) pneumonia or Chlamydia(C) pneumonia
Cases are eligible to be subjects in clinical trials if symptoms and findings for M pneumonia and C pneumonia are observed, and if they satisfy either (1) or (2) , and at least three of the other six criteria ( (3), (4), (5), (6), (7) or (8)).
(1) Chest X-rays or CT images project a newly developed shadow (shading is seen in the interstitium). (2) Pulmonary suppuration is a new name for pulmonary abscess and pulmonary gangrene. This disease is defined as suppurative necrosis of the lung parenchyma. The most important point in antimicrobial drug therapy for this disease is that primary pathogenic bacteria are anaerobes. Aerobes (Gram negative bacillus such as colibacillus and Gram positive coccus such as Streptococcus) follow and exacerbate infections originally due to anaerobes. Pulmonary suppuration is the second most common bacterial infection of the lung parenchyma (bacterial pneumonia is the most common). In regard to clinical trials, this disease can be regarded as the same as pneumonia. Therefore, trialsubject criteria for cases with pneumonia and evaluation methods for pneumonia can be used for this disease. However, anaerobes must be regarded as the important bacteria in microbiological testing in the case of pulmonary suppuration.
IV. Secondary infection of chronic respiratory illness
Disease outline
Patients with chronic bronchitis, bronchiectasis, diffuse panbronchiolitis (DPB), pulmonary emphysema or inveterate sclerosing tuberculosis often have recurring infections in the lower respiratory tract. Infections are based on organic changes in the lower respiratory tract.
Each infection is an acute infection that occurs in immune-compromised people. This disease is sometimes called a chronic respiratory tract infection because infection occurs repeatedly and without interval. We call this disease secondary infection of chronic respiratory illness. The most important bacteria of this infectious disease are Haemophilus influenzae, followed by pneumococcus and Moraxella catarrhalis. These bacteria are substituted by Pseudomonas aeruginosa after long term repeated infections, which results in refractory superinfection.
Disease level of subjects who are eligible to participate in clinical trials
In the case of secondary infection of chronic respiratory illness, the seriousness of the condition is assessed on the basis of the severity of the infectious disease and underlying disease/complication(s). Secondary infection of chronic respiratory illness is based on organic changes in the lower respiratory tract. Infection occurs repeatedly and without interval. Organic changes spread as the infection reoccurs. The original pathogenic bacteria are replaced by Pseudomonas aeruginosa. Pseudomonas aeruginosa causes superinfection and then becomes established. In this case, even if the severity of the infectious disease is mild, it is difficult to obtain antimicrobial effects from antimicrobial agents because organic changes in the lower respiratory tract are significant over a broad area. Therefore, the patient's condition is categorized as serious if (i) the severity of the under-lying disease/complication(s) is severe, even if the severity of the infectious disease is mild to moderate, or (ii) the severity of the infectious disease is severe and the severity of the primary disease/complication(s) is moderate. Currently, such cases are very difficult to treat and it is not appropriate to include such patients in the subject group. However, these patients must be treated with antimicrobial agents in actual clinical situations. In the future, it is necessary to develop an antimicrobial agent to treat these serious cases, and to conduct clinical trials of the antimicrobial agent as an independent or concomitant drug.
If organic changes in the respiratory tract of DPB patients are mild, the most common pathogenic bacteria at the time of onset of infection are Haemophilus influenzae followed by pneumococcus. However, these bacteria are more easily substituted with Pseudomonas aeruginosa in DPB patients than in patients with other secondary infections of chronic respiratory illnesses. As DPB patients develop opportunistic infections more frequently than patients with secondary infection of chronic respiratory illness and are more difficult to treat, it is at present inappropriate to include them in a group of subjects for a clinical trial. If organic changes in DPB patients are mild (DPB chest X-ray classification [by Tanimoto and Nakata]: type I [penetration increased, no granulated shading], type II [total granulated shading area not exceeding area of one lung], or type III [granule-shape shadows entirely cover the lungs but no "tramline shadows" or "ring shadows"]), these patients may currently be included in the subject-group. In the future, however, it will be necessary to include more severe cases such as type IV (findings of type III and "tramline shadows" in lower lung), and type V (findings of type IV and "ring shadows") for the same reason that we described above.
Trial-subject criteria for cases with M pneumonia and C pneumonia
Cases are eligible to be subjects in clinical trials if symptoms and findings of secondary infection of chronic respiratory illness are observed, and if they satisfy the following criteria. Prerequisites
(1) Onset of coughing and sputum, increase in sputum volume or puruloid sputum (2) Increase in CRP (м0.7 mg/dl, or CRP exceeds the upper limit of the relevant institute)
It is desirable to satisfy the following criteria. In regard to pleurisy, acute thoracic empyema (acute purulent pleurisy) caused by bacteria is included in the indications to be studied in clinical trials. The most common cause of this disease is the spread of inflammation from pneumonia or pulmonary suppuration to the pleura. The second most common cause is the spread of inflammation from a subphrenic abscess. Thoracic empyema sometimes occurs in patients with sepsis because bacteria have spread to the pleura via the blood. In some cases, it is not known where the bacteria enter the body or by which route it traveled.
The best cases to be subjects in these clinical trials are patients in which the inflammation caused by this disease is limited to the pleura. If patients suffer from inflammation of the organs adjacent to the pleura, they are not appropriate to be subjects. Patients with only a small amount of fluid in the pleural cavity, and who can be treated with drug therapy only (i.e. without drainage), are also suitable to be subjects.
As treatment for this disease is usually conducted within a hospital, drugs are mainly in the form of an injection. The severity of the infectious disease and underlying disease/ complication(s) in a patient who participates in a clinical trial should be moderate or less than moderate. If more than a certain volume of fluid is observed in patients and the severity of the infectious disease is more than moderate, it is practical to carry out antimicrobial therapy in conjunction with drainage. In this case, it is necessary to establish different evaluation criteria to evaluate the antimicrobial therapy.
III Approach to Each Phase of a Clinical Trial
The standard approach to developing antimicrobial agents is described in Guidelines for the Clinical Efficacy of Antimicrobial Agents (Notice No.743, August 25, 1998). This publication is based on researches by our society, and issued by the Evaluation and Licensing Division, the Pharmaceutical and Medical Safety Bureau, the Ministry of Health and Welfare. It presents clearly the objectives of each phase (phases I-IV) and the sequence of fundamental considerations in the development of antimicrobial agents.
By contrast, General Guidelines for Clinical Trials (Notice No. 380, Evaluation and Licensing Division, Pharmaceutical and Medical Safety Bureau, Ministry of Health and Welfare, April 21, 1998) recommends a diverse development style that is structured in accordance with the objectives of clinical trials, the circumstances, and the characteristics of the investigational product, rather than conventional uniform trials based on phase progression. In this publication, trials that are conducted in order to obtain approval are divided into three categories; they are clinical pharmacological studies, exploratory studies and confirmatory studies. In this publication, trials that are conducted after the product has been released to the market are called therapeutic use. The publication does not consider it appropriate to categorize clinical trials by phase because some trials involve several phases. The following figure demonstrates the relationship between the conventional trial delineation that is based on phase (phases IϳIV), and the trial delineation that is based on the new category recommenda- In this chapter, we describe clearly the objectives of each study category in accordance with General Guidelines for Clinical Trials.
Clinical pharmacological studies (mainly in phase I clinical trials)
These studies are conducted in order to determine the clinically safe dose-range of the investigational product, and to confirm the pharmacokinetics of the investigational product, such as absorption and excretion. The subjects of this study are usually normal adult male volunteers. In addition, this study aims to obtain information about the pharmacokinetics of the investigational product and its interactions with other drugs in a wide range of patient groups that are expected to receive it as a medication when it has been released.
(1) Tolerance evaluation
The studies in this category aim to confirm drug tolerance within the range of doses that are necessary for use in other studies conducted later in the clinical trial. They also aim to understand the characteristics of anticipated adverse events. Single-dose studies and repeated-dose studies are usually conducted. Dosage in single-dose studies is based on information obtained from non-clinical studies, previous clinical trials conducted in foreign countries, and similar types of drugs. In single-dose studies, the relationship between dosage and the onset of adverse drug reactions or abnormal laboratory test values is examined. Dose per administration in the repeated-dose studies are set to the maximum clinical dose that has been determined on the basis of the results of single-dose studies. The interval between administrations is the period that is necessary for the concentration of the drug in the blood to reach a steady state. If it is suspected that the investigational product will influence indigenous bacterial flora, or cause adverse drug reactions, these issues must be examined.
If the investigational product has the potential to be toxic to healthy people, it is necessary to examine the in vivo pharmacokinetics and possible adverse drug reactions using patients who suffer from the indications to be studied. In this case, it is necessary to determine the dose that is expected to be effective for the indications so that patients can benefit from the study.
(2) Pharmacokinetic and pharmacodynamic examinations
In pharmacokinetic studies, drug clearance is evaluated, and the possibility of unchanged drug and metabolite accumulation is investigated. In addition, the influence of meals on the pharmacokinetics is examined. Pharmacokinetic studies involving elderly people, children, and people with hepatic/renal dysfunction may be conducted if required. If necessary, drug interactions may be examined using drugs that may be used as concomitant drugs in clinical applications.
In addition, drug distribution to the lesion site will be studied.
In some cases, studies will compare the pharmacokinetics of Japanese and non-Japanese people in order to examine the validity of applying the results of clinical trials conducted in foreign countries to Japanese people.
Exploratory studies (mainly in phase II clinical trials)
These are small-scale studies conducted in order to explore safety and efficacy, to verify clinical dosage recommendations, and to explore the clinical characteristics of drugs.
If the recommended clinical dosage has already been established in reliable clinical trials conducted in foreign countries and there is sufficient information in regard to safety and efficacy, or if it is judged that the results of foreign clinical trials in regard to antimicrobial activities and pharmocokinetics/pharmocodynamics are applicable to Japanese people, it is possible to omit the exploratory study in Japan. In this case, the recommended clinical dosage for Japanese people must be confirmed in the confirmatory study.
(1) Exploring safety and efficacy
It is possible to infer the safe and effective dosage for antimicrobial agents from information such as the antimicrobial activity of the drug in regard to various pathogenic microorganisms, various measurements obtained from in vivo tests on small animals, the results of in vivo studies of pharmacokinetics, and information on similar drugs.
Studies in this category aim to examine whether the dosage that has been established on the basis of such information is appropriate.
Patients are excluded from these studies if they suffer from severe underlying diseases or take many types of medications because it is difficult to assess the safety and clinical underlying efficacy of the investigational product from these patients. In principle, the patients selected for the study are relatively similar. All patients are observed carefully. It is important to endeavor to isolate and identify the pathogenic bacteria. It is also important to understand the relationship between the sensitivity of the bacteria to the drug and the clinical/microbiological efficacy of the investigational product.
Subjects are selected from patients with upper respiratory tract infections, pneumonia or secondary infection of a chronic respiratory illness. All subjects are selected in accordance with the characteristics of the investigational product. Subjects must be between 16 and 79 years of age.
(2) Verifying recommended clinical dosage
Studies in this category may be conducted to confirm the safety of the estimated maximum clinical dosage. The safety of the estimated maximum clinical dosage is the primarily important aspect of this category for two reasons. Firstly, it is ethically unacceptable to set up a group of subjects who do not suffer from indications, because not only is clinical efficacy not likely to be observed, but it may also cause harm as antimicrobial agents are designed to treat acute illnesses. Secondly, the difference in dosage between the two groups is small, and it is therefore difficult to see the difference in efficacy between the groups. The dosage administered to a low-dosage group is the recommended clinical dosage that is anticipated to exert sufficient efficacy because administration of inadequate (too low) dosage of antimicrobial agents may decrease the sensitivity of the pathogenic microorganisms to the drug. The dosage administered to a high-dosage group is usually double the recommended clinical dosage, and is regarded as the estimated maximum clinical dosage.
If there is a significant difference between the two groups in regard to efficacy (clinical efficacy and microbiological efficacy) and/or safety, it is necessary to examine the validity of the recommended clinical dosage in the confirmatory study. Subjects are selected from patients with upper respiratory tract infections, pneumonia or secondary infection of a chronic respiratory illness. All subjects are selected in accordance with the characteristics of the investigational product. Subjects must be between 16 and 79 years of age.
(3) Exploring clinical characteristics
Studies in this category aim to explore the clinically advantageous characteristics of the investigational product. The investigational product will be evaluated on the basis of the efficacy variables that were established from the viewpoint of clinical benefit.
Efficacy (e.g. bacteria eradication rate, clinical efficacy for patients with infections due to unidentified pathogenic bacteria, acquired resistance, efficacy in regard to resistant bacteria, and the characteristics of bacteria that emerge after administration), speed of improvement in clinical conditions (time required for symptoms and finding to improve), compliance and safety (adverse drug reactions and abnormal laboratory test values) are evaluated.
Confirmatory studies (mainly in phase III clinical trials)
The objective of these studies is to confirm the clinical benefits.
In other words, these studies are conducted to verify that the investigational product is safe and effective for the treatment of the target indications. It is necessary to envisage patient-types to whom the investigational product will be administered when it is marketed, and to conduct the study by including these types of patients. In some cases, the study is planned to examine the use of the investigational product with concomitant drugs.
(1) Verifying non-inferiority or superiority of efficacy (Controlled studies: double-blind or open label)
Studies in this category aim to verify the safety and efficacy of the investigational product by comparing it with preexisting antimicrobial agents.
Subjects are selected from patients with acute tonsillitis, pneumonia or secondary infection of chronic respiratory illness. Subjects are selected in accordance with the characteristics of the investigational product. Control drugs are selected from marketed antimicrobial agents (regardless of type) for which the results of clinical evaluations have already been established. Control drugs are selected in accordance with the characteristics of the investigational product and indications to be studied. Subjects must be between 16 and 79 years of age.
In some cases, controlled studies with two investigational product groups (a recommended clinical dosage group and a maximum dosage group) and control group are conducted in order to confirm whether recommended clinical dosage of the investigational product is safe and exerts maximum efficacy.
(2) Confirming indications [expanding the range of indications] (General study: Open label study)
Studies in this category determine the indications and bacteria to be treated. These studies aim to expand the range of indications and obtain further information in regard to safety and efficacy.
The studies confirm the safety and efficacy toward indications that have not yet been tested in controlled studies. Subjects are selected from patients with upper respiratory tract infections, acute thoracic empyema or diffuse panbronchiolitis. Subjects are selected in accordance with the characteristics of the investigational product. Subjects must be 16 years or older.
Therapeutic use (primarily phase IV in clinical trials)
These studies aim to collect further information regarding appropriate usage of the investigational product when it is marketed.
(1) Drug Use Investigation
The pharmaceutical company that manufactures the investigational product conducts this investigation in order to collect information on adverse drug reactions (categorized by indication), quality, efficacy, safety and appropriate use. In collecting this information, the company does not set selection criteria for subjects.
(2) Special Investigation
The subjects in this investigation are patients who were excluded from the pre-approval clinical trials on the grounds that they had a clinically special background (e.g. children, elderly people, pregnant/parturient women and patients with hepatic/renal dysfunction, bacteriological sensitivity in post-marketing studies).
(3) Post-marketing studies
This is conducted, in compliance with GCP, in order to examine the issues that were not clarified during preapproval clinical trials, to verify information regarding appropriate use that was obtained from the drug use and special investigations, or to collect further information that has not been obtained in clinical consultations.
In post-marketing studies for antimicrobial agents, it is important to continue to examine drug sensitivity, as well as efficacy and safety, and to compare these results with results obtained prior to approval of the investigational product. It is also necessary to continue examination of interactions with concomitant drugs.
IV Consideration for the Characteristics of the Investigational Product and Administration Route
It is difficult to prepare one protocol that can be applied to all antimicrobial agents because they have different antimicrobial activities, different absorption, excretion and metabolism characteristics, different administration routes, and different indications. It is important for the protocol to document the important points to which attention should be paid in order to utilize the characteristics of the investigational product and evaluate clinical trials safely and objectively. Existing antimicrobial agents are classified according to their structure and the mechanism of their actions. In addition, adverse drug reactions and drug interactions that are typical of each type of antimicrobial agent have been confirmed. It is essential to examine these facts and check the category of the investigational product in order to establish appropriate inclusion/exclusion criteria and test parameters. If the investigational product belongs to a new category, it is necessary to establish these settings on the basis of various fundamental data.
It is not uncommon to have different efficacy and safety criteria for different microbial agents due to clinical trial types and available data in these trials. Therefore, when selecting the efficacy and safety criteria, it is necessary to comprehensively consider the characteristics of the investigational product, available data and the objectives of the clinical trial.
Important points in the development of -lactam antimicrobial agents
-lactam antimicrobial agents contain a -lactam ring in their structure. They demonstrate their antimicrobial activity by binding to penicillin binding protein (PBP), an enzyme that synthesizes the walls of the bacteria cells, and thereby inhibiting cell-wall synthesis. In Japan, many pharmaceutical products of this type (primarily cephem antimicrobial agents) have been developed and administered clinically because they have excellent selective toxicity and a strong antimicrobial activity. Many researches on drugs in this category were conducted in regard to their antimicrobial spectrum (which reflects their chemical structures), antimicrobial activities, tissue penetration, characteristic adverse drug reactions, and interactions with metabolic enzymes, even -lactamase inhibitors. Therefore, in developing new antimicrobial agents in this category, it is most important that they are distinguishable from existinglactam antimicrobial agents.
There is need for new cephem antimicrobial agents that have a stable chemical structure against ESBL S and/or stronger antimicrobial activities against S. aureus and P. aeruginosa. There is also need for new drugs that have excellent tissue penetration.
From a chemical structural point of view, a more stable structure is a desirable characteristic for new carbapenem antimicrobial agents. From a microbiological point of view, it is desirable for new drugs to provide an anti-MRSA activity equivalent to vancomycin (VCM) and to have increased binding affinity for PBP2 prime, and increased antimicrobial activities against Pseudomonas aeruginosa. In addition, it is expected that long-acting (prolonged half-life in blood) preparations with Class B -lactamase inhibitors will be developed. It is also expected that the oral form of carbapenem antimicrobial agents with a high level of bioavailability will be developed.
The important issues in regard to safety have largely changed over time and vary in accordance with type, such as penicillins, cephem antimicrobial agents or carbapenem antimicrobial agents. The primary concerns in regard to adverse drug reactions include anaphylactic shock, renal damage due to drug interactions, "Antabuse" action due to N-methylthiotetrazole group, coagulopathy and damage to the central nervous system due to the inhibition of γ-aminobutyric acid (GABA) receptors. There is a need for carbapenem antimicrobial agents that have attenuated nephrotoxicity and/or are less toxic to the central nervous system.
It is well established that penicillins and cephem antimicrobial agents are the safest -lactam antimicrobial agents, which have a long history. It is necessary to carefully investigate the safety of new -lactam antimicrobial agents, especially those with new chemical structures or additional group structures, without restricting safety considerations to the safety characteristics of existing drugs.
Macrolides
Macrolides have a lactone ring (12ϳ16-membered ring). They demonstrate their antimicrobial activity by binding with the 50S subunit of the 70S bacterial ribosome, and thereby inhibiting protein synthesis. They have a broad antimicrobial spectrum and are effective against anaerobes (for which lincomycin is ineffective), and pathogenic microorganisms of atypical pneumonia (for which -lactam antimicrobial agents are ineffective). They also have an inhibitory action on the formation of biofilm and bacteria-based enzymes and modulating effects on immune responses in the living body. A new macrolide that has a 15-membered ring and high intracellular penetration has recently been developed. This preparation demonstrates non-inferior efficacy compared to existing macrolides with a 14 or 16-membered ring. A new macrolide with an antimicrobial activity against resistant bacteria such as PRSP is needed. Ketolide, a new macrolide under development, does provide this type of action and is beginning to receive recognition.
It is more likely that macrolides with new chemical structures will be developed in the future. This means that new preparations will have new antimicrobial activities as well as different in vivo reactions. It is therefore necessary to conduct investigations in regard to drug efficacy from multiple directions.
In regard to safety, macrolides sometimes cause prolonged QT and increase the actions of muscle relaxants when used simultaneously. It is necessary to carefully investigate the safety of new macrolides, especially those with new chemical structures or additional group structures, without restricting safety considerations to the safety characteristics of existing drugs.
Quinolones
Quinolone antimicrobial agents inhibit DNA synthesis of bacteria by acting on DNA gyrase A, a type of topoisomerase that is necessary for DNA synthesis. Quinolones rapidly became common drugs in clinical situations because of their excellent bactericidal effects and intracellular penetration. New quinolones have a greater level of tissue penetration than ordinary quinolones, thus expanding the range of indications that can be treated. In developing quinolones, it is important to note that drug-resistant bacteria and acquired resistance should be fully investigated so that new quinolones with antimicrobial activities against resistant bacteria can be developed. It is expected that quinolones that have an antimicrobial activity against VRE, MRSA, PRSP, ESBL S , tubercle bacillus, Pseudomonas aeruginosa and anaerobes, and increased effects on biofilm will be developed, as well as an injection-type will be developed.
In regard to safety, the incidence and types of adverse drug reactions increased as the number of patients to whom quinolones were prescribed increased. Arthropathia, drug interactions, photosensitivity reactions and central nervous system related symptoms are already known to be adverse drug reactions. It is necessary to pay attention to hepatic dysfunction and prolonged QT as potential adverse drug reactions. Improved quinolones are needed with respect to adverse drug reactions.
When looking back over the history of the rapid development and marketing of quinolones, it can be said that it is necessary to determine points that differentiate the developmental drugs from the pre-existing drugs, and consider how we wish to apply the new drugs to treat indications when they are marketed. These issues should be considered in the early stages of development.
Aminoglycosides
Aminoglycosides have sugar chains and amino groups as substituents in their structure. They exert an antimicrobial activity by combining with bacterial ribosomes and thereby inhibit their protein synthesis. They have bactericidal effects on anaerobes, acid-fast bacteria, and general bacteria, with the exception of atypical bacteria. It is necessary to put safety first when developing aminoglycosides, as they have a neuroleptic action and may cause damage to the kidneys and/or ears. In particular, if patients are newborn babies, elderly people or patients with renal dysfunction, it is necessary to monitor drug concentrations in the blood in order to maintain concentrations within the safe ranges. It is possible to discover new advantageous characteristics during the development of aminoglycosides because these drugs influence the frequency of the emergence of resistant bacteria.
Tetracyclines
Tetracyclines consist of four rings with various substituents. They demonstrate an antimicrobial activity by binding with the 30S subunit of the 70S bacterial ribosome, and thereby inhibit protein synthesis. They have a broad antimicrobial spectrum (e.g. general bacteria, atypical bacteria, Rickettsia and non-fermentative bacteria). In regard to safety, it is necessary to pay careful attention to hepatic dysfunction. Some tetracyclines have antimicrobial activities against MRSA. New tetracyclines with stronger anti-MRSA activities are necessary to tackle the problems of resistant bacteria.
Other antimicrobial agents and important issues in the development of antimicrobial agents in the future
To date, glycopeptide antimicrobial agents, polypeptide antimicrobial agents, TMP/SMX, fosfomycin and mupirocin have been developed as new antimicrobial agents. They have new chemical structures, various mechanisms of action, and characteristic antimicrobial spectrums; and thus are distinguishable them from the existing antimicrobial agents.
At present, great attention is being paid to oxazolidinones that have proven antimicrobial activities against VRE, and streptogramins, both of which are under development. Development of new antimicrobial agents that are effective against various resistant bacteria is expected.
Important issues in the development of oral drugs and injections
It is important to establish a method of confirming that patients are complying with dosage and administration, and to communicate safety measures to patients in a way that is easy to understand. In order to do so, it is necessary to prepare a full range of clinical trial support tools in advance.
It has become recent practice to conduct low-dose studies for oral antimicrobial drugs. However, if a subject in this type of study is suffering from a respiratory tract illness, it is necessary to establish the appropriate dosage and administration from basic data in order to secure a sufficient level of drug concentration in the blood and tissue for drugs to exert antimicrobial activities.
The subjects in clinical trials for injections are usually inpatients, such as patients with severe infections and elderly people. Great consideration needs to be given to concomitant drugs and therapies, as well as resolvents. In some cases, it is necessary to consider possible concomitant drugs from the beginning of the development of injections, and conduct clinical trials accordingly.
Important issues in the development of antimicrobial agents in the future
In the future, when developing antimicrobial agents it will be necessary to consider the background of subjects, the medical environments in which the investigational product will be used, and the socioeconomic conditions.
The requisite characteristics of new antimicrobial agents include selective toxicity, strong antimicrobial activities, characteristic antimicrobial spectrums, tissue penetration and cell penetration. It is also necessary for new drugs to have metabolic pathways that will not be influenced by hepatic/renal functions. In order to provide antimicrobial agents in good time, it is necessary to have clear objectives for the clinical trial and design it very well by considering: the results of clinical trials conducted in foreign countries; demographics, such as subject population; and changes in the medical environment, such as medical insurance schemes.
In regard to safety, it is necessary to develop new antimicrobial agents that have fewer interactions with other drugs, including metabolic enzymes. In each case, it is necessary establish a method to prove that adverse drug reactions due to drug interactions can be easily treated.
V Outline of Clinical Trial Protocol
The following points should be kept in mind when using this protocol model. The sponsor of a trial is expected to draw up the protocol based on all components of this model. However, it should be noted that this model is merely an example that demonstrates how to prepare a protocol and the style that should be used. In other words, the indications studied, the observation and test parameters, and the primary efficacy and safety variable(s) should be set in accordance with the characteristics of the investigational product and the purpose of the development of the drug. Components should not be limited to those shown in this model. The sponsor may follow their own standard operating procedure (SOP) as long as the protocol satisfies the compulsory components of this model. Table (1) is an example of a protocol design of different phase clinical trials and their respective objectives. If the data is to be combined with data obtained overseas (bridging), the sponsor may wish to adopt the protocol-style of the country from which data was obtained. Nonetheless, the Bridging Study Committee has set out a guideline for bridging data, and the sponsor should follow the guideline. In this model, the points that should be kept in mind when preparing a protocol have been written within speech balloons. The most important points are that the protocol reflects the development strategy of the investigational product, and that the strategy is consistent throughout all phases of the clinical trial. However, it is scientific to draw up a different protocol with a new development strategy based on findings from the results of clinical trials. Designs and the indications studied for clinical trials should be determined in accordance with the characteristics of the investigational product and the objective of the trial.
If the indication is only upper respiratory tract infections due to the characteristics of the investigational product, the indication to be studied in the comparative test will be tonsillitis.
List of abbreviations and terms
Please refer to "Glossary of Chemotherapy" (Japanese Society of Chemotherapy). Confidentiality The information contained in this protocol is reserved by JSC Co., Ltd., and is provided only to medical institutions that wish to participate in this trial, the principal investigator, subinvestigators, clinical trial staff, and the institutional review boards. As such, the information may not be disclosed to third parties without permission from JSC Co., Ltd., with the exception of the subjects who consent to participate in the trial.
Example
The following components must be included in the protocol. of investigational product (Code) .......................................................................................................... name and structure ............................................................................................................................ I. Protocol Overview
Objective of the trial
To investigate/verify XXXX of JSC-0X (X mg) with respect to clinical efficacy/microbiological efficacy (administration period: 7 days or less) in patients with mild/moderate/severe acute respiratory tract infections, pneumonia, or secondary infection of chronic respiratory illness. The trial is a multicenter trial. Adverse drug reactions and abnormal changes in laboratory parameters will also be examined. 6) Patients suffering from an infection caused by a single type of microbe that is resistant to JSC-0X, and for which it is difficult to expect the drug to exhibit efficacy. 7) Patients who have participated in a previous clinical trial of this drug. 8) Other criteria based on the characteristics of the investigational product.
Subjects
If patients have been receiving drugs that interact with the investigational product, or long-acting antimicrobial agents that may influence evaluation of the efficacy of the investigational product, criteria appropriate to such drugs should be established.
Investigational product
1.3.1 Name of the investigational product Code: JSC-0X
1.3.2 Volume of the active ingredient, and dosage form JSC-0X is a tablet/capsule/ample that contains XX mg (titer). The preparation contains XXXX as an inactive ingredient.
Packaging of the investigational product
One JSC-0X tablet/capsule/ample is packaged in XXX.
Clinical trial design

This is an open/double-blind exploratory/confirmatory multicenter trial. Administration will generally be seven days (168 hours) (possibly eight calendar days). However, administration will be terminated prematurely or discontinued within this period if the Objective of the therapy is achieved or the patient meets the discontinuation criteria described below. If a longer administration period is necessary, the drug may be administered for up to 14 days (or 15 calendar days).
Clinical trial period
From XX/XX/XX to XX/XX/XX 1.4.6 Target population XXX cases
Pretreatment and concomitant therapies
The following drugs and therapies are prohibited for use in conjunction with the investigational product. However, when these drugs or therapies are deemed necessary for the benefit of the subject, administration of the investigational product will be discontinued. If it is found that the subject is receiving these drugs or therapies, administration of the investigational product will be discontinued. 1) Other oral antimicrobial agents or antimicrobial injections 2) Human immunoglobulin preparations 3) Colony-stimulating factor preparations (G-CSF etc.) 4) Adrenocorticosteroids (equivalent to 10 mg or more of prednisolone per day by means of inhalation or general administration) 5) Continuous administration of antipyretic analgesics (Occasional use is acceptable.) 6) Other drugs and medical instruments under development 7) Bronchial washing 8) Other drugs that should be prohibited due to the characteristics of the investigational product 1.5 Observation, test and investigation parameters
Observation, test and investigation parameters
Observations and tests will be conducted in accordance with the following chart.
Flow chart
This clinical trial will be conducted in the following sequence. 1) Confirm that subjects fulfill the inclusion criteria, and that they should not be excluded on the basis of the exclusion criteria. All subjects who are informed of the clinical trial will be recorded on the Screening List, regardless of whether they consent to participate. 2) The pre-administration examinations that are necessary for the trial will be conducted following the obtainment of consent.
3) The investigational product will be administered in accordance with the "Dosage and administrations of the investigational product". Subjects receive the necessary instructions. 4) Planned observations and tests will be conducted on a specified day. Results for each item will be evaluated and assessed. 5) The principal investigator or subinvestigators will check for any adverse events that have occurred between the day of commencement of administration of the investigational product and the final observation day. If adverse events have occurred during this period, the principal investigator or subinvestigators will conduct a follow-up. 2) Abnormal changes in laboratory parameters Abnormal changes in laboratory parameters will be assessed on the basis of Assessment Criteria for Adverse Drug Reactions and Abnormal Changes in Laboratory Parameters in Clinical Trials for Antimicrobial Agents (Japanese Society of Chemotherapy).
Efficacy and safety variables and evaluation method
2)
II. Protocol
Background and history
The following points should be documented in accordance with the characteristics of the investigational product. Origin and history of development Name of the investigational product and relevant explanations Summary of clinically important findings obtained in non-clinical trials and previous clinical trials Summary of the known and potential risks and benefits to human subjects Description of population, objective and method, and justification for this clinical trial References (guidelines etc.)
Good clinical practice (GCP)
This clinical trial will be conducted in accordance with: 1) Declaration of Helsinki (a statement of ethical principles to provide guidance to physicians and other participants in medical research involving human subjects); 2) Clause 3, Article 14, and Clause 2, Article 80 of the Pharmaceutical Affairs Law, as well as Ordinance No. 28 of the Ministry of Health and Welfare, Guideline for Good Clinical Practice (which came into force on April 1, 1997).
The principal investigators, in association with the sponsor, agree to the contents of the protocol and case report forms. The principal investigators also pledges, prior to conducting the clinical trial, that he or she will comply with the protocol and case report forms in all respects.
Administrative structure of the clinical trial
This clinical trial is planned and conducted by the administrative structure that consists of the following members.
Sponsor
Sponsor-investigator
Each member and their role should be described. 
Objective of the trial
To investigate/verify XXXXX of JSC-0X (X mg) with respect to clinical efficacy/microbiological efficacy (administration period: 7 days or less) in patients with mild/moderate/severe acute respiratory tract infections, pneumonia, or secondary infection of chronic respiratory illness. The trial is a multicenter trial. Adverse drug reactions and abnormal changes in laboratory parameters will also be examined.
The specific efficacy or safety variables (primary/secondary variables) that clarify the clinical characteristics of the investigational product should be described here as the target to be investigated or verified. Targets may vary in accordance with the phase and design of trials.
Type of trial
Phase X clinical trial Multicenter/Monocenter Exploratory/Confirmatory Trial
Subjects
Indications studied
The indications studied or the bacteria treated should be set in accordance with the characteristics of the investigational product or objective of the trial. For example: atypical pneumonia may be set as the indication studied in accordance with the characteristics of a drug; panbronchiolitis may be set as the indication studied in accordance with the objective of the trial; or, in order to distinguish pneumonia that is caused by community acquired infection from pneumonia that is caused by hospital acquired infection, one of the two types of pneumonia would be set as the indication studied.
The indications to be studied are the following mild/moderate/severe respiratory tract infections that are (possibly) caused by microbes sensitive to JSC-0X.
1) Acute respiratory tract infections
Upper respiratory tract infections (acute tonsillitis, acute pharyngitis and acute laryngopharyngitis) and acute bronchitis, peritonsillar abscess and retropharyngeal abscess 2) Pneumonia, pulmonary abscess and acute thoracic empyema 3) Secondary infection of chronic respiratory illness Chronic bronchitis, bronchiectasis, pulmonary emphysema, bronchial asthma, pulmonary fibrosis and inveterate pulmonary tuberculous
Inclusion criteria
Criteria should be set in accordance with the objective of the trial.
Patients who meet the following criteria will be included in this trial.
Refer to the agreements for each phase.
1) Outpatients/inpatients (male/female) who are over XX and below XX years of age on the day of consent. 
Exclusion criteria
Patients will be excluded from this trial on the basis of the following criteria. Criteria should be set for each characteristic of the investigational product. When doing so, criteria should be described concretely (e.g. using grades in Severity Categorization Criteria for the Adverse Drug Reaction of Pharmaceutical Products. Notice No. 80 issued by Safety Division, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare.
3) Patients who have been receiving other antimicrobial agents and whose medical conditions are improving. 4) Female patients who are known to be, or suspected to be, pregnant, or lactating.
An explanation of pregnancy testing procedures and guidance in the use of contraceptives should be included if the drug is suspected to be reproductively or developmentally toxic.
5)
Patients who have participated in other clinical trials of drugs, either within the past one month, or in the case that the period since the last administration of other clinical trial drugs is less than 5 times the half-life of those drugs. 6) Patients suffering from an infection caused by a single type of microbe that is resistant to JSC-0X, and for which it is difficult to expect the drug to exhibit efficacy. 7) Patients who have participated in a previous clinical trial of this drug. 8) Other criteria based on the characteristics of the investigational product.
Subject enrollment list
The principal investigator will prepare a list of the subjects who have consented to participate in this trial. The list will include the initials, sex, date of consent and ID codes for each subject.
Patient information and consent
The consent form and written information
The principal investigator(s), in association with the sponsor, will prepare, or amend if necessary, the consent form and any written information in order to obtain consent from subjects to participate in the clinical trial. These documents will be supplied to the sponsor to obtain approval from the institutional review board(s) of the trial site(s).
The content of the written information
Refer to a sample prepared by the informed consent composition committee.
The following points will be included in the written information, which includes any amended documents. Furthermore, the principal investigator or subinvestigators should provide a full explanation of these points when obtaining consent from the subjects.
1) The trial involves research
2) The objective of the trial 3) The method of the trial (aspects of the trial that are experimental, inclusion criteria and probability of treatment assignment) 4) The expected duration of each subject's participation in the trial 5) The approximate number of subjects involved in the trial 6) The reasonably foreseeable clinical benefits, risks or inconveniences to each subject (If there are no intended clinical benefits to a subject, the subject should be made aware of this fact.) 7) The alternative treatment that may be available to each subject, and their important potential benefits and risks 8) Compensation and treatment available for subjects in the event of trial-related injury 9) Each subject's participation in the trial is voluntary and any subject may refuse to participate, or may withdraw from the trial, at any time, without penalty or loss of benefits to which the subject would otherwise be entitled. 10) Each subject will be informed, in a timely manner, if information becomes available that may be relevant to their willingness to continue to participate in the trial. 11) The conditions that apply to a subject withdrawing from the trial (If a subject is withdrawn from the trial, reasons will be provided.) 12) The monitor, the auditor, the institutional review board, and the regulatory authority will be granted direct access to subjects' original medical records, but will not violate the confidentiality of any subject. By signing the written informed consent form, the subject is authorizing such access. 13) The identity of all subjects will remain confidential, even though the results of the trial may be published. 14) Anticipated expenses (if any) 15) Anticipated payment (if any) and how the amount is determined 16) The name, position and contact number/address of the principal investigator or subinvestigators 17) The person of the trial site who can be contacted for further information regarding the trial and the rights of trial subjects, and the person who should be contacted in the event of trial-related injury 18) Each subject's responsibilities
Timing and method of obtaining consent
If consent by a subject's legally acceptable representative is necessary, the method by which consent is obtained should be documented.
Prior to the clinical trial, the principal investigator or subinvestigators will use the consent form and other written information to provide each subject with a full explanation of the trial and the rights of subjects. The principal investigator or subinvestigators will then obtain consent that is freely given by each subject. (Each subject must print their name, sign or stamp, and date the consent form.) The principal investigator or subinvestigators will record, on the subject-enrollment list, the names of each subject who received an explanation of the trial. The physician (and physician's assistants) who provided the explanation will print their names, sign or stamp, and date the consent form.
The principal investigator or subinvestigators will check whether any subject is also under the care of another physician. If so, the subject's participation in the trial will be reported to the subject's physician, on agreement with the subject. The principal investigator or subinvestigators will record on the case report form the date that the information was sent to the subject's physician.
The principal investigator, subinvestigators or trial staff will provide each subject with a copy of the informed consent form and the other written information. The originals will be stored in a specified location at each trial site.
Important points in regard to obtaining informed consent
The following points are regarded as important in obtaining informed consent. 1) The principal investigator or subinvestigators should not coerce or unduly influence any subject to participate or to continue to participate in a trial. 2) Information should not contain any language that causes any subject to waive or to appear to waive any legal rights, or that releases or appears to release the investigator, trial staff, the medical institution or the sponsor from liability for negligence.
3) The language used in information should be as nontechnical as practicable and should be understandable to the subject.
Amending the consent form and written information (adding new information)
If the sponsor obtains information that may be relevant to any subject's willingness to continue to participate in the trial, the sponsor will promptly inform the head of each trial site and the principal investigator in writing. The principal investigator or subinvestigators will promptly inform all subjects and ask each one whether they wish to continue to participate in the trial. Consent will need to be given again in the knowledge of the revised information. Communication of the new information to each subject should be documented. If a subject is an outpatient, consent (with their printed name, signature/stamp, and date) will need to be obtained at his/her next visit.
The principal investigator will, in a timely manner, revise the consent form and written information based on the new information that has become available, and then obtain approval from the institutional review board. The preparation contains XXXX as an inactive ingredient.
Packaging and labeling
Packaging: One JSC-0X tablet/capsule/ample is packaged in a XXXXXXX that is stored in a pharmaceutical box (white box, * cm ϫ * cm ϫ * cm). The following label will appear on the box. The investigational product should be stored at room-temperature/in a cool place/freezer. (Keep away from light). Expiration date: XXXXXX, 200X. officer etc.) once the clinical trial contract has been concluded with the institution. Delivery will be carried out by the monitor. The drug management officer will receive the invoice, check the quantity and print his/her name on the receipt and sign or stamp it.
Storage and management of the investigational product
The head of each medical institution will assign a drug management officer to store and manage the investigational product. The drug management officer etc. will store and manage the investigational product in accordance with the storage conditions stated in the "Instructions for handling the investigational product", which will be prepared by the sponsor. The drug management officer will also draw up the investigational product handling record form in which prescribed quantities and other relevant information will be recorded.
The drug management officer, the principal investigator, subinvestigators and trial staff will handle the investigational product in accordance with the instructions for storage. If the expiration date of the investigational product has passed and it is necessary to replace the product with a new batch, the sponsor will reclaim the unused portion of the drug and replace it.
Reclaiming the investigational product
In reclaiming the investigational product, the sponsor will check the quantities of used and unused portions of the drug and issue a certificate of reclamation to the drug management officer etc. The drug management officer etc. will print his/her name on the drug return form and sign/stamp it. He/she will submit a copy of the investigational product management record form to the sponsor.
Instructions for management of the investigational product
The sponsor will prepare the "Instructions for handling the investigational product" and submit these instructions to the head(s) of the medical institution(s).
Analysis of the investigational product
A third party organization, or similar, will analyze the investigational product prior to supplying it to the drug management officer etc. in order to confirm that the product conforms to the set standards. The same examination will be conducted by a third party organization at the completion of the trial.
Clinical trial design
Type of clinical trial
This is an open/double-blind exploratory/confirmatory multicenter trial.
Flow chart
This clinical trial will be conducted in the following sequence. 1) Confirm that subjects fulfill the inclusion criteria, and that they should not be excluded on the basis of the
Supplying the investigational product
The sponsor will deliver the investigational product directly to the drug management officer or person assigned by the drug management officer (hereinafter, drug management exclusion criteria. Informed consent is obtained. All subjects who are informed of the clinical trial will be recorded on the Screening List (Attachment 2), regardless of whether or not they consent to participate. 2) The pre-administration examinations that are necessary for the trial will be conducted following consent.
3) The investigational product will be administered in accordance with "8.5 -Administration dosage and method".
For example, instruct subjects to take the drug within 30 minutes following meals in the case of an oral drug. Provide a full explanation and written instructions on how to take the drug for all subjects at the time of consent.
4) Planned observations and tests will be conducted on a specified day. Results for each item will be evaluated and assessed. 5) The principal investigator or subinvestigators will check for adverse events that have occurred between the day of commencement of administration of the investigational product and the final observation day. If adverse events have occurred during this period, the principal investigator or subinvestigators will conduct follow-up.
Randomization and blinding
In the case of comparative trials, it is necessary to include the following documentation (8.2 and 8.3).
The XXXX method for randomization and blinding will be used in order to minimize selection bias. The randomization and blinding procedures will be documented.
Treatment assignment list, and composition and storage of an emergency key code
The person responsible for assigning the investigational product will randomize the group of subjects using the XXX method in order to divide subjects into a JSC-0X group and a control group. The investigational product will be assigned in accordance with the randomization method (e.g. using the sequence of the assignment numbers of the drug/ placebo and sequence of the subject ID codes). The person responsible for assigning the investigational product will seal the treatment assignment list and store it safely and attentively until the time of unsealing. The person responsible for assigning the investigational product will make an emergency key code and ensure that the code is broken only in accordance with the decoding procedure that has been specified.
Efficacy and safety variables
Primary efficacy and safety variables
Suitable primary efficacy and safety variables should be set in accordance with the characteristics of the investigational product and the objective of the clinical trial. 
Secondary efficacy and safety variables
There has been an increase in bridging studies in recent years, and some clinical trials have used the assessment criteria and methods that are used in Western countries. As such, the timing of assessment may vary. It is therefore necessary to investigate and carefully consider these issues in accordance with the characteristics of the trial when selecting variables. The primary and secondary variables should be clearly distinguished in accordance with the objective of the trial.
1) Efficacy
(1) (2) 2) Safety (1)(2)
Administration dosage and method
Once informed consent has been obtained, the principal investigator or subinvestigators will administer the investigational product orally/intravenously in accordance with the dosage and administrations shown in the table below.
Volume per dose Frequency (per day)
᭺ϫ mg X times ᮀ mg Y times
Administration period
The period should be set in accordance with the objective of the trial.
E.g. 7-day administration period Administration will generally be seven days (168 hours) (possibly eight calendar days). However, administration will be terminated early or discontinued within this period if the objective of the therapy is achieved or the patient meets the discontinuation criteria described below. If a longer administration period is necessary, the drug may be administered for up to 14 days (or 15 calendar days).
Duration of the clinical trial
The duration of the clinical trial is between the day of consent and the final observation day.
The trial does not necessarily finish at the completion of the administration of the investigational product.
Target population XXX cases
Pretreatment and concomitant therapies
Pretreatment and meals
The rules regarding pretreatment and meals should be described. In particular, rules should be drawn up in regard to antimicrobial agent(s) that have been administered prior to the administration of the investigational product.
Concomitant drugs and therapies
If particular concomitant therapies are conducted, the procedures and prohibitions governing these therapies should be described.
The name of the concomitant drug that will be used during the clinical trial, the dosage and administrations, duration and indications treated during the clinical trial will be recorded on the case report form. In the case of a concomitant therapy, the name, method, duration and indications treated will be recorded on the case report form. Drugs or therapies used in the treatment of an adverse event will be recorded in the section, "Action taken for adverse event" on the case report form.
Prohibited concomitant drugs and therapies
These drugs and therapies should be set up in accordance with the characteristics of the investigational product or clinical trial. The drugs for which careful attention is required when used in conjunction with the investigational product should be described in a different section (8.9.4).
The drugs and therapies listed below are prohibited for use in conjunction with the investigational product. However, when these drugs or therapies are deemed necessary for the benefit of the subject, administration of the investigational product will be discontinued. Administration of the investigational product will be discontinued for any subject found to be receiving any of these drugs or therapies. 1) Other oral antimicrobial agents or antimicrobial injections 2) Human immunoglobulin preparations 3) Colony-stimulating factor preparations (G-CSF etc.) 4) Adrenocorticosteroids (equivalent to 10 mg or more of prednisolone per day by means of inhalation or general administration) 5) Continuous administration of antipyretic analgesics (Occasional use is acceptable.) 6) Other drugs and medical instruments under development 7) Bronchial washing 8) Other drugs that should be prohibited due to the characteristics of the investigational product (e.g. Valproic acid when carbapenem is the investigational product, and NSAID when new quinolone is the investigational product.) 8.9.4 Concomitant drugs and therapies that need careful attention Interactions are known to occur between the drugs similar to the investigational product and the drugs and therapies that are listed below. If these drugs are being used, careful attention and consideration must be given to their influence on the efficacy of the investigational product and the benefits to the subject.
The drugs and therapies should be specified in accordance with the characteristics of the investigational product and clinical trial. Example: Theophylline when new quinolone is the investigational product; The clinical trial that is assessing the efficacy of the investigational product when it is used in conjunction with a small dose of macrolide; Local therapy around the tonsils or pharynx of patients with acute respiratory tract infections (use of antimicrobials, disinfectants, anti-inflammatory drugs, tonsillectomy, pharyngectomy and puncture); A small dose of aspirin as an antithrombotic; Use of NSAID.
Maintenance of blinding
In the case of the comparative test, the following sections (8.11 and 8.12) are also necessary.
Blinding will be carried out using the randomization procedure. This will be conducted by the person responsible for assigning the investigational product. The investigational product will be indistinguishable from the control drug.
The treatment assignment list will be stored (by the person responsible for assigning the investigational product) until the time of unsealing. Blindness will be maintained for all people relevant to this clinical trial, except for the person responsible for assigning the investigational product.
The sponsor will prevent unblinding by reclaiming the investigational product after the clinical trial has been completed and the treatment assignment list is unsealed. If the investigational product is reclaimed prior to unsealing, blindness will be maintained by the person responsible for assigning the investigational product by checking the quantities of the unused investigational product, place them in the original box, seal the box, and return it to the sponsor.
Unsealing procedure
The treatment assignment list will be unsealed after all case report forms are completed and the data for analysis is finalized.
Efficacy and safety variables and flow chart
Observation parameters, test parameters and investigation parameters, and timing
The parameters and timing of observations and tests will vary in accordance with the objectives of the clinical trial or the characteristics of the investigational product.
Observation parameters, test parameters and investigation parameters 1) Patient information
The following subject information will be described in the case report form: Subject ID code, initials, date of birth, sex, weight, (height), type of patient (outpatient/inpatient), name of diagnosed infectious disease and its severity, as well as the name, stage and severity of the underlying disease and complications, the seriousness of the patient's condition, disease history, allergy history, and any antimicrobial agents that were administered during the period beginning 7 days prior to the commencement of administration and ending on the day before the commencement of administration of the investigational product. The underlying disease and all complications will be documented and circled if there is any possibility that they will influence the indications studied. The severity of infectious diseases, the underlying disease, and complications will be assessed on the basis of the severity criteria for infectious diseases and the severity criteria for the underlying disease and complications set down in Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy). 1) The following categories will be used for assessment and the appropriate category will be documented in the case report form. 1. Mild 2. Moderate 3. Severe 2) Efficacy evaluation parameters (1) Subjective symptoms and objective findings
The following symptoms and findings will be investigated on a day specified for consultation or interview. The symptoms and findings investigated for acute respiratory tract infections are body temperature, cough, pharyngeal pain, tonsil pain, coating of pus, the accumulation of pus, purulent secretion, redness and swelling. The symptoms and findings investigated for pneumonia and secondary infection of chronic respiratory illness are body temperature, cough, sputum (volume and type), chest pain, breathing difficulty, rhonchus, dehydration and cyanosis. Observed symptoms and findings will be recorded in the case report form in accordance with the following criteria. If body temperature is measured more than once in one day, the highest temperature for that day will be recorded. [3] Sputum volume: The following five levels ϩϩϩϩ (100 mL or more per day) ϩϩϩ (50 mL or more and not more than 100 mL per day) ϩϩ (10 mL or more and not more than 50 mL per day)
ϩ (Not more than 10 mL per day) Ϫ (None) [4] Sputum type: P (purulent), PM (purulent and mucous), M (mucous) [5] Breathing difficulty: ϩϩ (Hugh-Jones: more than ((), ϩ (H-J: (), Ϫ (none) [6] Chest pain: ϩ (yes), Ϫ (no) [7] Rhonchus: ϩϩ (significant), ϩ (mild), Ϫ (none) [8] Dehydration: ϩ (yes), Ϫ (no) [9] Cyanosis: ϩ (yes), Ϫ (no) (2) Chest X-rays (pneumonia and secondary infection of chronic respiratory illness) It is beneficial to perform CT scans of the chest, in addition to chest X-rays. Chest X-rays will definitely be taken prior to the commencement of administration and seven days following the commencement of administration (or at the time of completion/discontinuation). A sketch will be drawn in the case report form. If the subject is suffering from pneumonia, compulsory X-rays will also be taken three days after the commencement of administration. (3) Microbiological testing
In the case of acute respiratory tract infections, microbes will be isolated from the eiterbelag/plug of pus, the purulent secretion, or a pharynx swab, then identified and counted. In the case of pneumonia and secondary infection of chronic respiratory illness, microbes will be isolated from sputum, and then identified and counted. This will be done in order to identify the pathogenic bacteria and microbe substitute. The results will be recorded in the case report form. Even if the microbes that are detected are the microbes that form normal microflora, the name of each species of microbe will be recorded on the form. Smear testing and Gram's staining of the sputum will be conducted in accordance with the smear specimen preparation procedure. The results and comments of the findings will be documented in the case report form.
<Test for drug sensitivity to pathogenic bacteria and microbe substitute>
The pathogenic microbes and microbe substitute that are separated at each medical institution will be sent to the central laboratory facility in order to measure their sensitivity to drugs. As a general rule, serial dilution for measuring the MIC will be prepared in accordance with NCCLS rules. If the MIC and microbiological efficacy clearly do not match, it will be beneficial to change the microbial volume for measuring the MIC and/or measuring MBC. 3) Safety evaluation parameters (1) Adverse events i) Definition of an adverse event Any unfavorable medical occurrence happening between the commencement of administration of the investigational product and the final observation (in a patient who has received the investigational product), regardless of the existence of a causal relationship with this investigational product. However, events that occur due to the investigational product's lack of efficacy will be assessed to determine whether they are adverse events by considering the nature and degree of each event. In general, adverse events include the following. [1] The onset or deterioration of the condition of subjective symptoms and objective findings, the deterioration of the condition of the underlying disease and complications, and the onset of coincidental symptoms In order to collect information on an adverse event that has occurred in a subject following administration of the investigational product, the principal investigator or subinvestigators will conduct an investigation, (between the commencement of the administration of the investigational product and the final observation day) by documenting the subject's voluntary report and the interview findings. If any observed adverse events do not disappear (or if the subject does not recover) during the clinical trial period, a follow-up investigation will be conducted following the completion of the clinical trial, and the outcome will be documented in the case report form. [2] Abnormal changes in laboratory parameters If clinically significant abnormal values are observed in laboratory tests between the commencement of administration of the investigational product and the time of completion or discontinuation of administration, and these values do not normalize (or do not return to the previous levels), a follow-up investigation will be conducted following the completion of the clinical trial. The results will be documented in the case report form.
The adverse event follow-up period should be established in accordance with the characteristics of the investigational product. In all cases, the original observation period should continue until the final observation day; Laboratory tests (especially invasive tests) during the follow-up period are not compulsory, except in the case that the laboratory test at the end of the adverse event follow-up period is set as compulsory in the clinical trial protocol, or when the principal investigator or subinvestigators regard it as clinically necessary.
4) Laboratory tests
The laboratory parameters that are considered necessary to evaluate safety should be established in accordance with the characteristics of the investigational product.
The serum antibody tests (Mycoplasma antibody titer, Chlamydia antibody titer and Legionella antibody titer) do not need to be conducted on any specific day because of the time it takes for the values to become positive.
Special tests for determining the pathogenic bacteria should be clearly documented in accordance with the clinical trial. Recently, if Mycoplasma, Chlamydia or Legionella are the microbes treated in a clinical trial, identification by means of culturing or PCR, may be required in addition to immunological testing.
5) Therapies following the completion or discontinuation of administration of the investigational product
The principal investigator or subinvestigators will record the therapies undertaken between the completion or discontinuation of administration of the investigational product and the final observation day. Whether the use of antimicrobial agents during this period is necessary or not will be considered very carefully because it will influence the final evaluation. If agents are used, the objective of their use will be clearly documented on the case report form.
If antimicrobial agents are used before the final evaluation, the final evaluation will be regarded as "Indications studied were not cured". Therefore, the use of antimicrobial agents following administration of the investigational product as a means of preventing a recurrence of the disease should be considered very carefully.
6) Follow-up for subjects who do not visit the hospital (trial site) If any subjects do not visit the hospital and it is difficult to continue treatment, the principal investigator or subinvestigators will contact them by telephone, letter, or other means of communication in order to encourage them to visit the hospital. It may be necessary to conduct the follow-up over the telephone. The date of investigation, drug taking status, reasons for not continuing to visit, and whether or not there is or was an adverse event will be documented in the case report form. It will be recorded in the case report form that the follow-up cannot be conducted (due to relocation or change of residence etc.), if such is the case. 7) Drug-taking instructions and drug-taking status If the investigational product is an oral drug, this title should be as above. If the investigational product is an injection, a title such as "Status of administration" should be written at this section and instructions for recording the status in the case report form should be described here.
Example for an oral drug The principal investigator or subinvestigators will instruct subjects to bring their drug-taking diary and the remaining investigational product, every time they visit. The principal investigator or subinvestigators will check the drug-taking status of each subject and record it in the case report form.
Flow chart
Observations and tests will be conducted in accordance with the above table. The results will be recorded on the case report form.
Efficacy and safety variables and evaluation methods
Efficacy evaluation 1) Efficacy evaluation three days after the commencement of administration (1) Clinical efficacy (three days after the commencement of administration)
The clinical efficacy of the investigational product will be assessed on the basis of the subjective symptoms, objective findings and laboratory test values (and shading in the chest X-rays in the case of pneumonia) between or during the period prior to the commencement of administration and three days after the commencement of administration. The clinical efficacy evaluation criteria in Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy) 1) will be used. The results of the assessment (one of the following categories) will be documented in the case report form. 1. Effective 2. Ineffective 3. Not possible to assess 2) Efficacy evaluation at the end of treatment (EOT) (1) Clinical efficacy (EOT)
The clinical efficacy of the investigational product will be assessed on the basis of subjective symptoms, objective findings and laboratory test values (and shading in the chest X-rays in the case of pneumonia) between or during the period prior to the commencement of administration and the completion or discontinuation of administration. The clinical efficacy evaluation criteria in Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy) 1) will be used. The results of the assessment (one of the following categories) will be documented in the case report form.
1. Effective 2. Ineffective 3. Not possible to assess (2) Assessment of shading in chest X-rays If the subject is suffering from pneumonia, chest X-ray shading will be assessed on the basis of the criteria in Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy).
1) The score (between 0ϳ11) will be recorded in the case report form. (3) Microbiological efficacy for each species of pathogenic bacteria The name of microbes that are thought to be pathogenic bacteria will be circled on the case report form. Furthermore, the pathogenic bacteria will be determined by comprehensive consideration of the progress of each subject's clinical condition, as well as the microbiological test results. The information obtained from the results of the quantitative culture and Gram's staining will also be considered for evaluation. If Gram's staining is evaluated, it is important to see the degree of engulfment by neutrophils. 1. Disappeared 2. Decreased 3. Unchanged 4. Not possible to assess Among the species of bacteria detected at the completion or discontinuation of administration, the name of the species of bacteria that are suspected to have emerged following administration will be marked on the case report form.
<Bacteria that emerged following administration>
The species of bacteria that emerged following administration were those whose numbers were below the detection limit in the test prior to the commencement of administration but were detected following the com-mencement of administration. The qualitative and quantitative measurements for these species at the completion of administration (or at the final observation) are 2 ϩ or more, and 10 4 cfu/ml or more, respectively.
However, Neisseria, α-Streptococcus and other nonpathogenic microbes in the respiratory tract will be excluded unless there are legitimate reasons for their inclusion. If a subject's condition is assessed as superinfection, the newly detected bacteria will be treated as having emerged following administration, even if the qualitative and quantitative measurements for such bacteria are less than the figures stated above. (4) Microbiological efficacy (EOT) i) Pathogenic bacteria Microbiological efficacy will be assessed on the basis of results of the tests conducted prior to administration, three days after the commencement of administration, and at the completion or discontinuation of administration. The microbiological efficacy evaluation criteria in Clinical Evaluation Methods for New Antimicrobial
Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy) 1) will be used. One of the following categories will be recorded in the case report form. In the assessment of efficacy, comprehensive evaluation, as described in section (3), is required. 1. Disappeared (or thought to have disappeared) 2. Decreased 3. Partially disappeared 4. Unchanged 5. Not possible to assess ii) Bacteria that emerged following administration The emergence or otherwise of bacteria following administration will be assessed at the time of the completion or discontinuation of administration and will be documented in the case report form. Such bacteria will be assessed in terms of the following categories, and one of the categories will be recorded. 1. Overgrowth of microbe substitute (Infections and/or symptoms due to the bacteria that emerged following administration are not observed.) 2. Superinfection (Infections and/or symptoms due to the bacteria that emerged following administration are observed.) 3) Efficacy evaluation at the final observation (end of study: EOS) The evaluation methods and assessment criteria will be described when the final evaluation is drawn up.
Example (1) Final evaluation
For cases in which administration of other antimicrobial agents was not necessary, the final observation will be conducted following the completion or discontinuation of administration of the investigational product, and assessment will be conducted on the basis of the following criteria. If administration of other antimicrobial agents is carried out, the final evaluation will be assessed as "Indications studied were not cured". <Cases in which EOS and EOT are at different times from each other>
The final evaluation will be based primarily on the assessment of clinical efficacy at the EOS (7 to 10 days following the completion or discontinuation of administration for cases of acute respiratory tract infections and pneumonia, and 7ϳ21 days for cases of secondary infection due to chronic respiratory illness). One of the following assessment categories for the clinical efficacy will be recorded on the case report form. 1. Cured (or effective) 2. Uncured (or ineffective) 3. Not possible to assess <Cases in which EOS and EOT are at the same time>
The final evaluation will be based on the clinical and microbiological efficacy at the EOS (7 to 10 days following the completion or discontinuation of adminis-tration for cases of acute respiratory tract infections and pneumonia, and 7ϳ21 days for cases of secondary infection due to chronic respiratory illness). One of the following assessment categories will be recorded in the case report form. 1. Cured 2. Uncured 3. Not possible to assess The following is an example of assessment criteria for the final evaluation.
Safety evaluation 1) Abnormal laboratory test values
The laboratory test values will be assessed to determine whether they are normal or abnormal. This assessment will be documented in the case report form. Abnormality will be defined as any deviation from the standard range of values set by each trial site. If the test is carried out at the central laboratory facility, standard range values will be those set by the central laboratory. If the trial site does not have standard range values for any of the parameters, the principal investigator or subinvestigators will set the standard range values for these parameters by referring to the "Guideline for Laboratory Test Methods" etc. and submit the values to the sponsor. The results of these parameters will then be assessed accordingly. 2) Adverse events (1) Documentation of adverse events in the case report form [1] Onset or deterioration of subjective symptoms and objective findings, deterioration of underlying disease or complications, and the onset of coincidental symptoms If an adverse event such as the onset or deterioration of subjective symptoms and objective findings, deterioration of the underlying disease or complications, or the onset of coincidental symptoms occurs between or during the period before the commencement of administration of the investigational product and the final observation day, the principal investigator or subinvestigators will document, in the case report form, the type of adverse event, the day of onset, action taken, the outcome, severity, seriousness, causal relationship with the investigational product, and the basis of assessment. This documentation will be carried out in accordance with the assessment criteria set out in the following section.
[2] Abnormal changes in laboratory parameters The principal investigator or subinvestigators will document the parameters whose values change from "normal" to "abnormal", or which were "abnormal" and deteriorated, between or during the period prior to the commencement of administration of the investigational product and the completion or discontinuation of administration. This documentation will be carried out with reference to the standard range of values specified by the trial site and "Assessment criteria for adverse drug reactions and abnormal changes in laboratory parameters in clinical trials of antimicrobial agents".
2) The principal investigator or subinvestigators will assess whether these changes are clinically significant or not. The reasons for those assessed as "not significant" will be documented in the case report form. The name of the laboratory parameters assessed as "significant", as well as the date on which they are verified, action taken, outcome, severity, seriousness, causal relationship with the investigational product, and the basis of each assessment will be documented in the case report form in accordance with the assessment criteria set out in the following section. (2) Assessment criteria for adverse events [1] Type of adverse event The type of each adverse event will be recorded in the case report form. If the adverse event is an abnormal change in laboratory parameters, the name of the parameter and the change (increase or decrease) will be recorded in the case report form.
[2] Date of onset The date of the onset, or the date that the event was discovered, will be recorded in the case report form. [3] Action taken in response to the adverse event i) Administration status of the investigational product The administration status of the investigational product will be assessed and one of the following categories will be recorded in the case report form. 1. Continuing/Completed 2. Amount decreased/Temporarily suspended 3. Discontinued In the case of discontinuation, the person responsible for the decision (the subject or physician) will be specified in the case report form. ii) Action taken It will be recorded in the case report form whether or not action was taken in response to each adverse event. If action was taken, the details will also be recorded. [4] Outcomes of adverse events The outcome of each adverse event will be assessed in terms of one of the following categories, and the date on which it is verified will be recorded in the case report form.
i) The onset or deterioration of the condition of subjective symptoms or objective findings, the deterioration of underlying disease or complications, or the onset of coincidental symptoms If the outcome is unknown, the reasons for this situation will be documented in the case report form. [5] Severity of adverse events The severity of each adverse event will be assessed by referring to the "Assessment criteria for adverse drug reactions and abnormal changes in laboratory parameters in clinical trials for antimicrobial agents" 2) , and one of the following categories will be recorded in the case report form.
1. Mild 2. Moderate 3. Severe [6] Seriousness of adverse events All adverse events will be assessed to determine whether they are serious or not by referring to the definition of "serious adverse event". If assessed as serious, it will be recorded on the case report form.
Serious 2. Not serious
[7] Causal relationship with the investigational product Each causal relationship with the investigational product will be assessed in terms of one of the following categories. The basis of assessment will also be documented in the comments column.
1. Definitely related An adverse event will be regarded as definitely related if a clear correlation is observed with respect to timing (the period following the discontinuation of administration will be included), and evidence that indicates a clear relationship is observed, such as that described below.
• Similar symptoms/signs were observed when the investigational product was accidentally readministered.
• Drug sensitivity tests (lymphocyte culture test, skin test etc.) are positive.
Probably related
An adverse event will be regarded as probably related if a clear correlation is observed with respect to timing (the period following the discontinuation of administration will be included) and factors such as the primary disease, complications, concomitant drugs and concomitant therapies will be excluded as possible causes.
Possibly related
An adverse event will be regarded as possibly related if a clear correlation is observed with respect to timing (the period following the discontinuation of administration will be included) and factors such as the primary disease, complications, concomitant drugs and concomitant therapies are suspected as the cause, but the investigational product cannot be excluded as the cause. 4. Not related An adverse event will be regarded as not related if a clear correlation is not observed with respect to timing (the period following the discontinuation of the administration will be included).
If an adverse event is assessed as 1, 2 or 3, it is regarded as "related to the investigational product" and is categorized as "abnormal changes in laboratory parameters due to the investigational product" or an "adverse drug reaction".
Safety assurance for all subjects
Fundamental
Appropriate selection criteria will be set so that subjects for whom safety is not guaranteed cannot be enrolled in the trial. The results of the screening tests will be used to determine whether subjects will be enrolled or not. During the clinical trial, it will be ensured that investigators are always aware of the condition of the health of each subject by means of daily observation in the case of inpatients, and observation at every visit in the case of outpa-tients. A method of contact will be prearranged in case of emergency. Collection and communication of safety information considered to be related to the investigational product will be carried out continuously. When an adverse event occurs, the safety of subjects will be assured through the provision of the appropriate medical treatment, such as decreasing the dosage or discontinuing administration of the investigational product. An adverse event investigation method (which would be conducted by the efficacy and safety evaluation committee), treatment for the serious adverse event, and the procedure for decoding during the clinical trial will be established. These rules will ensure that there will be communication with the trial site(s), that decisions regarding continuation/discontinuation of the clinical trial will be taken appropriately, and that the safety of subjects will be assured. This committee will be established if assessment by an independent organization consisting of physicians who are not involved in the clinical trial is necessary because additional attention must be paid to safety and clinical efficacy within the trial, or because the primary efficacy and safety variables of the trial are subjective. If the committee is established, the objectives and roles of the committee should be described. Example XXXX, the indication studied, sometimes involves a serious outcome. Therefore, the sponsor will collect the case report form of each subject who received the investigational product. If a problem arises, it will be reported to this committee. Safety and clinical efficacy will be examined by this committee, and the feasibility of continuation of the clinical trial will be assessed. This committee will provide the results of their examination and assessment to the sponsor.
Serious adverse events
10.2.1 Definition of a serious adverse event (1) Death (Leading to death) (2) Event that may lead to death (Life-threatening) (3) Event that requires the subject to be hospitalized or the duration of hospitalization to be extended to allow for treatment (4) Disability (permanent or significant disability or dysfunction) (5) Event that may lead to disability (Medically important condition) (6) Serious event that ranks below any of the events described in (1) to (5) (Medically important condition) (7) Congenital disease or abnormality in progeny (Event that brings congenital anomaly) (8) Any event that the principal investigator or subinvestigators judge as serious (9) Any event that the sponsor judges as serious 10.2.2 Action taken at onset The principal investigator or subinvestigators will carry out appropriate emergency treatment for the following serious adverse events, and ask specialists to diagnose the event in order to determine the cause. If a relationship between an adverse event and the investigational product cannot be ruled out, the principal investigator or subinvestigators will promptly (i.e. within 24 hours of discovery) report the adverse event to the head of each trial site and the sponsor (monitor), either in person, by telephone or fax. (This will apply to all adverse events except those categorized "not related".) The principal investigator or subinvestigators will then submit the "Serious adverse event during clinical trial (brief report)" form within three days, as well as the "Serious adverse event during clinical trial (detailed report)" within ten days to the head of the trial site and the sponsor. Furthermore, the head of the trial site will provide the principal investigator with instructions, based on the recommendations of the institutional review board, in regard to the continuation of the clinical trial. The principal investigator or subinvestigators will report on the adverse events that were judged to have no causal relationship with the investigational product (events categorized as "not related") in the same manner as described above. The adverse events will be reported within 24 hours of discovery. The brief report will be submitted to the head of the trial site and the sponsor within three days, and the full report will be submitted within ten days.
Decoding procedure during the clinical trial
This section should be included in the comparative test.
If an adverse event occurs and the principal investigator or subinvestigators judge that unblinding is necessary to protect the safety of subjects, the decision will be reported to the sponsor. The sponsor will first confirm that the contents of the case report form of the subject who had the adverse event is finalized, and then ask the person responsible for assigning the investigational product, to break the emergency key codes.
Expected adverse drug reactions
Expected adverse drug reactions (including abnormal changes in laboratory parameters)
The adverse drug reactions and abnormal changes in laboratory parameters that are expected, on the basis of results from non-clinical studies and previous clinical trials, are shown below. The adverse drug reactions and abnormal changes in laboratory parameters to which attention needs to be paid, are also shown below. The principal investigator, subinvestigators, and the trial staff will all be well aware of these reactions in order to ensure the safety of subjects. 1) Important points from the results of the non-clinical studies Important points from the results of the basic studies (non-clinical studies) should be described here.
Example
It is known from XXX test that it has mutagenicity. Therefore, long-term use of high doses should be avoided.
Reactions that occurred in previous clinical trials should be described here.
2) Adverse drug reactions and abnormal changes in laboratory parameters that were observed in previous clinical trials By the phase ϫϫ clinical trial, ᭺ϫ was observed in ϫϫ% of subjects (᭺᭺/ϫϫ) and ᮀ was observed in ϫϫ% of subjects (ᮀᮀ/). Abnormal changes were observed in (parameter). Therefore, attention should be paid to such reactions and changes when examining subjects. The onset or deterioration of subjective symptoms and objective findings, deterioration of underlying disease and complications, and the onset of coincidental symptoms The principal investigator or subinvestigators will conduct appropriate treatment and take all possible measures to ensure the subject's safety until the reaction attenuates or the principal investigator or subinvestigators judge that no further treatment is necessary. The reactions will be documented in detail in the "Adverse event" section. Even if action cannot be taken because the subject has changed residence or hospital, follow-up by means of telephone or letters will be conducted to determine the outcome. The findings of the follow-up will be documented in the case report form.
2) Abnormal changes in laboratory parameters
In the case that the principal investigator or subinvestigators judge that the abnormal changes in laboratory parameters are clinically significant, the principal investigator or subinvestigators will continue to observe the values until they return to within the standard range or improve, or the principal investigator or subinvestigators judge that no further observation is necessary. The findings from observation will be documented in the case report form.
Discontinuation criteria and procedure
Discontinuation criteria
The principal investigator or subinvestigators will cease administration of the investigational product to the subject if any of the following criteria apply.
(1) Subject or next-of-kin request (2) No improvement is observed in the condition of symptoms and findings and it is judged that continuation is not appropriate. (3) Continuation is difficult due to the onset of an adverse event. (4) The condition of the underlying disease/complications has deteriorated and it is judged that continuation is not appropriate. (5) It is found, after the commencement of the clinical trial, that a subject's disease is not included in the indications studied. (6) It is found that the subject does not satisfy the inclusion/ exclusion* criteria after the commencement of the clinical trial. (7) It is judged that administration of prohibited concomitant drugs is necessary. (8) The subject does not visit the trial site. (9) Other criteria for which the principal investigator or subinvestigators accept the necessity of the discontinuation. * If the subject was not excluded on the basis of the exclusion criteria at the commencement of administration, but he/she comes into conflict with the criteria due to a change in condition during the period of administration, the principal investigator or subinvestigators will judge whether continuation of administration of the investigational product is inappropriate (difficult) or not. If continuation is judged as appropriate (possible), the reason for the judgement will be documented in the case report form.
Discontinuation procedure
If the principal investigator or subinvestigators become aware of any subject who should not continue on the basis of the discontinuation criteria (11.1), or any of the following three situations occurs, administration of the investigational product will be discontinued for that subject and the situation will be explained to the subject. EOS observations and tests will be conducted at the time of discontinuation. Following discontinuation, subjects will receive alternative therapy or appropriate treatment. Outpatients will be notified by telephone and instructed to cease taking the investigational product and to visit the trial site promptly for an alternative therapy or appropriate treatment.
(1) The sponsor instructs the principal investigator(s) or subinvestigators to prematurely terminate or suspend the entire clinical trial (refer to 14.2). (2) The sponsor instructs the principal investigator or subinvestigators to prematurely terminate or suspend the clinical trial at a specific trial site (refer to 14.3).
(3) A principal investigator decides to prematurely terminate or suspend the clinical trial due to concerns about the safety of the investigational product.
Statistical analysis
Quality control and assurance of data
Quality control of data
The monitoring committee and data management committee will control the quality of data in accordance with "standard operating procedures". The sponsor will implement and maintain quality control systems to ensure the reliability of the data that are relevant to the clinical study at each stage of data handling. Finalization of case information (collection of case report forms, data checks, input, changes and amendments) and management of the data prior to the time of analysis will be carried out in accordance with standard operating procedures.
Quality assurance of data
The quality of data will be assured by the quality assurance department
Target population XX cases
Determination of sample size
It is important to determine the sample size before commencing the trial. In comparative tests, consideration should be given to ensuring that the balance is not biased against the control drug.
The case selection criteria for efficacy and safety (adverse drug reactions and abnormal changes in laboratory parameters) evaluation will be as follows. Cases that are selected for analysis are regarded as the "per protocol set" (PPS). Cases that do not meet GCP will be excluded from the samples for all efficacy evaluations. Cases to which the investigational product will not be administered will be excluded from all evaluations.
Efficacy
Cases will be adopted for the sample group to evaluate efficacy if the investigational product was taken/administered for three days or more, and if the principal investigator or subinvestigators assessed final clinical efficacy. However, cases that violate any of the following criteria will be excluded. [1] Cases that deviate from the inclusion criteria or meet the exclusion criteria.
[2] Cases that do not satisfy the selection criteria for evaluation set down in Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy).
1 [3] Correct dosage and administrations are not maintained.* [4] Prohibited concomitant drugs/therapy are involved. [5] Cases that violate the discontinuation criteria [6] Cases in which observations were not recorded at the commencement, at the time of discontinuation, or at the completion of administration. * As a general rule, cases in which 80ϳ120% of the expected total volume of the investigational product (from the commencement until the completion or discontinuation) has been taken/administered can be included. However, cases in which drug-taking/administration has been missed on two consecutive occasions will be excluded.
If the investigational product is a drug requiring one administration daily, appropriate criteria should be set.
Safety (Adverse drug reactions)
Cases in which the investigational product has been taken/ administered at least once will be included.
12.3.3 Safety (Abnormal changes in laboratory parameters) Cases for which the specified parameters have been tested prior to the commencement and at the time of discontinuation or completion of administration will be included. However, cases in which the tests were conducted during and at the time of discontinuation or completion of administration will be included in each safety evaluation parameter in accordance with the following table. Cases in which abnormal changes in laboratory parameters have been observed will always be included.
Statistical analysis plan 1) Purpose of analysis
Assessment variables that should be explored/confirmed in the clinical trial should be described here. In regard to clinical efficacy, the efficacy rate will be the number of cases in which the clinical efficacy is assessed as "effective" in proportion to the total number of valid cases selected for efficacy analysis. In regard to microbiological efficacy, the efficacy rate will be the number of cases in which microbiological efficacy is assessed as "disappeared" in proportion to the total number of valid cases selected for efficacy analysis, with the exclusion of cases in which microbiological efficacy was "Not possible to assess".
In regard to safety, all adverse events whose causal relationship with the investigational product cannot be denied will be regarded as adverse drug reactions/ abnormal changes in laboratory parameters. The incidence of adverse drug reactions will be the number of cases in which adverse drug reactions occurred in proportion to the total number of valid cases that were selected for safety analysis of adverse drug reactions.
The incidence of abnormal changes in laboratory parameters will be the number of cases in which abnormal changes in laboratory parameters occurred in proportion to the total number of valid cases that were selected for safety analysis of abnormal changes in laboratory parameters. The actual number of cases for each reaction/parameter will not be shown.
The incidence of each type of adverse drug reaction will be the number of cases of each type in proportion to the total number of valid cases selected for safety analysis of adverse drug reactions. The incidence of abnormal changes in each laboratory parameter will be the number of cases in which abnormal changes in each laboratory parameter occurred in proportion to the total number of valid cases that satisfy the selection criteria for safety analysis (as described in 12.3.3).
(2) Analysis of the secondary efficacy and safety variables
The following demographic characteristics and characteristics of other standard values will be summarized or analyzed. Sex, age, weight, (height), names of diagnosed infectious diseases, the severity of the infectious diseases, the existence of an underlying disease/complications (and severity, if any), the existence of a primary disease/ complications that may influence the infection, the seriousness of the subject's condition, body temperature, cough, sputum volume, sputum type, WBC count and CRP. In the case of pneumonia, chest X-ray shading will be included.
If pathogenic bacteria were analyzed, the name of the species (or genus) will be used for categorization. The microbiological efficacy for each bacteria (disappearance rate) will be the number of cultures that were assessed as "disappeared" in proportion to the total number of valid cultures for efficacy analysis, with the exclusion of cultures that were categorized as "Not possible to assess".
In regard to the clinical efficacy three days after the commencement of administration, the efficacy rate will be the number of cases in which clinical efficacy was assessed as "effective" in proportion to the total number of valid cases selected for efficacy analysis.
In regard to changes in symptoms/signs, analysis will be carried out using all the cases that are valid for efficacy analysis.
The cure rate at the final evaluation assessment will be the number of cases that were categorized as "cured" in proportion to the total number of valid cases for efficacy analysis.
6) Others
It should be remembered that exploratory analysis (analysis that was later added to the planned analyses) is not primary analysis.
If necessary, exploratory analysis will be carried out in order to determine the efficacy and safety characteristics of the investigational product.
7) Interim analysis
If interim analysis is conducted, the objective and methods will be described. The timing of analysis will be set in accordance with the objective of the clinical trial.
Compliance, deviation, change and amendment of the clinical trial protocol 13.1 Compliance with the protocol
This clinical trial will be conducted in accordance with the protocol, as agreed to by the principal investigator(s) and the sponsor.
Deviation from the protocol or changes to the protocol
If any change to the protocol has the potential to significantly influence the clinical trial or increase the risk to which subjects are exposed, the principal investigator must submit the proposed protocol amendment to the institutional review board of the trial site. The proposed protocol amendment must be reviewed and approved before enrolling any new subjects. A principal investigator cannot amend the protocol without prior agreement of the sponsor, and without prior review and documented approval from the institutional review board, except where necessary to eliminate an immediate hazard(s) to the trial subjects, or when the change(s) involve only administrative aspects of the trial.
If a principal investigator changes the protocol to eliminate an immediate hazard(s) to the trial subjects, documentation of the implemented change will be submitted to the head of each trial site, the institutional review board, and the sponsor.
Amendment of the protocol
Amendment of the protocol will be decided through discussion between the principal investigator(s) and the sponsor. The institutional review board will arrange the discussion if necessary. If it is decided to amend the protocol, the sponsor will notify the principal investigator and head of each trial site. Notification will be in writing and will include the amendments and the reasons for the change.
14. Completion, premature termination or suspension of the clinical trial
Completion of the clinical trial
The following situation will be regarded as the completion of the clinical trial.
1) The completion of administration of the investigational product (end of treatment: EOT) If a final observation is to be included in the protocol, it should be noted that the completion of administration of the investigational product (end of treatment: EOT) is not the completion of the clinical trial (end of study: EOS). (1) The drug-taking/administration of the investigational product is complete. (The investigational product was taken/administered for seven days {or eight calendar days} or the specified administered volume was taken/ administered, and the efficacy assessment was conducted at the completion of administration.) [Example of the 7-day administration period] (2) It was judged that the objective of the treatment was achieved.
2) Completion of the clinical trial
The final observation was conducted and the specified tests and evaluations were carried out (end of study: EOS).
The principal investigator will submit the EOS report (including the GCP compliance status) to the head of the trial site as soon as the clinical trial is complete. The head of the trial site will notify the institutional review board and the sponsor, and provide them with a summary report.
Premature termination or suspension of the entire clinical trial
The sponsor will prematurely terminate or suspend the entire clinical trial if continuation of the clinical trial becomes impossible due to the onset of serious adverse events, etc. If such a situation arises, the sponsor will promptly notify the head of each trial site and inform them of the premature termination or suspension of the entire clinical trial and the reason for it. Notification will be in writing. The head of each trial site will notify the principal investigator and institutional review board, in writing.
Premature termination or suspension of the clinical trial at a specific trial site
The sponsor will prematurely terminate or suspend the clinical trial at a specific trial site if any of the following situations occur. If any such situations arise, the sponsor will promptly notify the head of the trial site and inform them of the premature termination or suspension of the entire clinical trial and the reason for it. Notification will be in writing.
The head of the trial site will notify the principal investigator and the institutional review board, in writing. Upon receiving the notice, the principal investigator will follow the procedure specified at the trial site. 1) The continuation of the clinical trial becomes impossible due to the onset of serious adverse events. 2) The trial site breaches ordinance No. 24 (related to GCP), the protocol, or the clinical trial contract, and as a result, a correct clinical trial cannot be carried out. In such cases, the contract with the trial site will be cancelled and the clinical trial at the trial site will be prematurely terminated (except when it is necessary to eliminate an immediate hazard(s) to trial subjects, or in other medically important cases).
Case report form
Composition and submission of the case report form
The principal investigator or subinvestigators will fill in the case report form for each subject from whom consent was obtained as soon as the final observation is conducted or participation is discontinued. If a subinvestigator fills in the case report form, the subinvestigator will print his/her name and sign or stamp the form and submit it to the principal investigator for verification of the contents. The principal investigator will print his/her name and sign or stamp the form once it has been confirmed as valid. The signature or stamp that are used on the case report form will be the same as that on the "list of signatures and stamps" that will be submitted to the sponsor before preparing the case report form.
Changes or amendments to the case report form
Changes or amendments to the case report form will be conducted in accordance with the following procedure.
(1) The principal investigator or subinvestigators will prepare, change or amend the case report form in accordance with the "Instruction guideline for preparing, changing or amending the case report form", which will be produced separately and in advance. (2) To change or amend a record, rule double lines through the original parts, making sure that the original parts are still readable. Write the date, and sign or stamp the alteration. The signature and stamp of the principal investigator or subinvestigators must be that which appears in the section "Name of the principal investigator or subinvestigators". If the amendment is major or significant (i.e. the date of consent, causal relationship, evaluation assessment and drug-taking status), the reason and date of the amendment will be written and signed or stamped. (3) In the case that a member of the trial staff changes or amends the case report form, rule double lines through the original parts, as described above, and write the date of the change/amendment. The principal investigator or subinvestigators must sign or stamp the changed/ amended part. (4) If changes or amendments to the case report form become necessary, the principal investigator will make a record of the changes or amendments to the case report form and submit the record to the sponsor. (5) If a part of the case report form is changed or amended after the principal investigator has confirmed its contents (i.e. the date of the changes/amendments is later than the date of composition), the principal investigator will check the changed/amended part and write the date of confirmation, print his/her name and sign or stamp the alteration each time it is necessary. (6) The principal investigator will store a copy of the case report form and other records including records of the changes or amendments to the case report form.
Cautions for filling in the case report form
Trial staff may fill in the case report form (e.g. copying demographics, observations and test results from the original source), except for any information that is related to medical evaluation and assessment.
(1) The "JSC-0X clinical trial case report form" will be used. (2) The principal investigator or subinvestigators will prepare, change or amend the case report form in accordance with the "Instruction guideline for preparing, changing or amending the case report form", which is produced separately and in advance. (3) Pen or ballpoint pen will be used so that writing cannot be erased. (4) The case report form will be prepared for all subjects from whom consent is obtained. However, for subjects who did not receive the investigational product, only the sections for demographics, observations and test results will be filled in. (5) Insert a dash (or similar) for items not tested or examined in order to distinguish these parts from parts that have been overlooked. (6) Confirm that the data in the case report form are consistent with the source data. If there is any contradiction, the principal investigator will prepare a report on this matter stating the reason and submit the report to the sponsor. (7) The principal investigator or subinvestigators will confirm all contents; sign or stamp the changed/amended part; print his/her name and sign or stamp in the section "Name of the principal investigator or subinvestigators"; and write the date of composition/confirmation.
Direct access to the source data/documents
Specifying the source documents
The source documents should be specified in advance in accordance with the characteristics of the clinical trial.
The following items are not always recorded on the patient's card (or similar) within the trial site. Therefore, the information written in the case report form or the test results attached to the case report form will be regarded as the source documents for these items. 
The monitor was appointed by the sponsor
The monitor will directly access the source documents in order to confirm that there are no contradictions between the patient cards at the trial site and the case report forms. The monitor will apply for direct access to the source documents in accordance with the method specified by each trial site, and access them on a designated date and in a predetermined manner. The principal investigator or subinvestigators will review the work of the monitor, and change or amend, if necessary, the contents of the case report form, in accordance with the procedure for changes/ amendments.
Quality control and assurance for the clinical trial
Quality control
Quality control and assurance will be achieved by complying with GCP; as well as by standardizing the methods of preparing the case report form, the handling and management of the case report form and source data, the monitoring, direct access to the source data, evaluation and assessment; and by investigating the appropriateness of such methods.
Compliance with GCP
This clinical trial will be conducted in accordance with the protocol, and in compliance with the Declaration of Helsinki and Clause 3, Article 14 and Clause 2, Article 80 of the Pharmaceutical Affairs Law and GCP.
The principal investigator(s), in association with the sponsor, agree to the contents of the protocol and case report form, and pledge, prior to conducting the clinical trial, that they will comply with the protocol and case report form in all respects. 17.1.2 Management and handling of the case report form data The sponsor will implement and maintain quality control systems to ensure the reliability of the data that are relevant to the clinical study at each stage of data handling. Finalization of case information (collection of case report forms, data checks, input, changes and amendments) and management of data prior to the time of analysis will be carried out in accordance with standard operating procedures.
Monitoring
The monitor will be appointed by the sponsor. The monitor will provide necessary information on conducting the clinical trial to the principal investigator(s), subinvestigators, trial staff and drug management officer(s), as well as explain and discuss the procedure of the clinical trial (protocol) and the method of managing the investigational product.
The monitor will visit the trial sites periodically (or when the need arises) during the clinical trial period and conduct the following activities. deviations from the protocol and GCP, and take appropriate action to prevent any recurrence of the deviations.
Direct access to the source documents
The principal investigator and clinical trial site will make available all source documents or other relevant documents at the trial site in order to assist the investigations of the monitor, auditor, the institutional review board or regulatory authority. These investigations are carried out in order to verify that the clinical trial is being carried out appropriately, and that the reliability of the data is maintained.
17.1.5 Standardization and validity of evaluation and assessment 1) Efficacy is assessed on the basis of the clinical efficacy assessment criteria set down in Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy). 1) 2) Microbiological tests will be carried out at the central laboratory and trial sites. The tests will be conducted in accordance with the standard operating procedures established at each institution. 3) Abnormal changes in laboratory parameters will be assessed by referring Assessment criteria for adverse drug reactions and abnormal changes in laboratory parameters in clinical trials of antimicrobial agents (Japanese Society of Chemotherapy).
2) For the parameters whose criteria are not documented, the principal investigator or subinvestigators will form their own assessment on the basis of standard medical practice. 4) The validity of the evaluation and assessment (diagnosis, severity of disease, clinical efficacy, microbiological efficacy, chest X-ray shading and safety) by the principal investigator or subinvestigators will be verified by the clinical trial coordinating committee for each case. The issues raised by the committee will be discussed with the principal investigator or subinvestigators. The principal investigator will consider the discussion and make a final decision on each issue.
Quality assurance
The following activities will be conducted by the sponsor's auditing department.
Ethical conduct of the clinical trial
Institutional review board
Review
The validity of this clinical trial will be investigated by the institutional review board that is nominated by the head of the trial site. If the institutional review board orders a change in the protocol, the principal investigator and subinvestigators of each trial site, the clinical trial coordinating committee and the sponsor will discuss the issue and formulate a response. The sponsor will submit the updated versions of the following documents to the head of the trial site if the institutional review board requests such.
1) Protocol (whose contents will have been agreed to by the principal investigator(s)) 2) Case report form 3) Consent form and written information (prepared by the principal investigator) 4) The investigator's brochure 5) Documents related to the anticipated costings of the clinical trial 6) Documents related to the payment (if any) of subjects and compensation for trial-related injury 7) Resumes of the principal investigator(s) and subinvestigators 8) Up-to-date documents related to the status of the clinical trial (If the trial has continued for one year or more, documents should be submitted at least once a year, or when the institutional review board requests them.) 9) Documents related to the safety of subjects (serious adverse event report, new important information) 10) Other documents that the institutional review board considers necessary
Continuous review by the institutional review board
The institutional review board will continuously review the clinical trial if necessary. Moreover, if the trial has continued for one year or more, the institutional review board will request up-to-date documents that describe the status of the trial at least once a year in order to ensure the clinical trial is being conducted safely.
Protection of human rights
Ethical conduct of the clinical trial
18.2.3
The confidentiality of subjects Careful attention will be paid to the protection of the human rights of the subjects. The identity of each subject will remain confidential by using initials and a subject ID code. The monitor, auditor, institutional review board and regulatory authority will maintain the confidentiality of each subject when they access source data.
Storing records
The sponsor
The GCP record management officer will be appointed by the sponsor. The GCP record management officer will store all documents and records required to this trial (the request for the clinical trial, records, the minutes of the institutional review board, reports on the results of discussions, contracts, the clinical trial protocol, case report form, the comprehensive clinical trial report, the database, and records and test results related to analyses). The documents and records will be stored for the period specified in Clause 2-3, Article 26 of the Regulations of the Pharmaceutical Affairs Law. All documents and records required to this trial are specified in the GCP. When the investigational product has been approved for manufacture, or a decision has been made to discontinue its development, the sponsor will notify the clinical trial site in writing.
The principal investigator
The head of the clinical trial site will place the principal investigator in charge of storing records. He/she will be responsible for storing records in accordance with the regulations at the trial site and section 19.3.
Clinical trial site
The person who is appointed by the head of the clinical trial site to be responsible for storing records, will store documents and records that are required by GCP to be stored at the trial site (source documents, contracts, consent forms, written information and instructions on handling the investigational product). He/she will store these documents for three years from either the date of approval for manufacture as a pharmaceutical product, the date of the early termination of the clinical trial, or the date of the completion of the clinical trial, whichever occurs last. The documents will be stored in a location specified by the trial site. When the specified period for storage has elapsed, the person responsible for storing records will obtain approval from the sponsor before destroying any documents. If the place of storage changes due to moving etc., a record of the new location will be maintained. The head of the trial site and the person responsible for storing the records will ensure that records are not lost or destroyed, and will make available any records required during the moving process.
When the storage period has elapsed, the sponsor will notify the trial site.
Payment and insurance
Payment
In a multicenter trial, each trial site may have their own regulations in regard paying the subjects (e.g. payment may be payment in kind). Therefore, this section (20.1 Payment) may be written separately to the main protocol.
XXXX yen per visit will be paid to outpatients as a cooperation fee/transportation expenses. XXXX yen will be paid to inpatients at the times of hospitalization and discharge during the trial period. In regard to the method of payment, each trial site will comply with their own regulations.
Compensation for trial-related injury and insurance
The sponsor will take out the following insurance in order to compensate subjects for trial-related injury.
• Type of insurance and the name of the insurance company [1] Type of insurance (e.g. General liability insurance that includes clinical trials) [2] Name of insurance company
If the subject receives a trial-related injury, the medical institution will treat the subject and take any other necessary action. The sponsor will be liable for compensation for trial-related injury, as may arise. The subject will not bear any expenses in obtaining proof, such as proof of a causal relationship between the injury and this clinical trial. If the medical institution is obliged to compensate the subject, the sponsor will reimburse the medical institution for all expenses, except in the following cases. 1) A significant deviation from GCP or the protocol by the principal investigator or subinvestigators (except for medically unavoidable circumstances such as to eliminate immediate hazards to the subjects) 2) Intentional or non-intentional malpractice and/or negligence by the principal investigator or subinvestigators 3) Self-induced injury or negligence on the part of the subject If compensation or reparation is necessary due to trialrelated injury, the medical institution will notify the sponsor promptly.
Agreement on publication
When any person involved in this clinical trial intends to present the results or information in the public arena, such as at conferences or in journals, he/she will discuss the contents of any such publication with the sponsor in order to obtain approval. The confidentiality of subjects will be maintained in the publication.
The basis for components
The scientific basis for each component should be described here by referring to materials such as guidelines.
1) Clinical trial design
The trial will be designed along the lines of a clearly defined objective and the specific characteristics of the investigational product. The basis for the design will be described in accordance with Guidelines for Clinical Efficacy of Antimicrobial Agents. 4) 2) Inclusion criteria The basis for the inclusion criteria will be described by referring to Guidelines for Clinical Efficacy of Antimicrobial Agents 4) and Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy). 1) 3) Exclusion criteria
The basis for the exclusion criteria will be described by referring to Guidelines for Clinical Efficacy of Antimicrobial Agents 4) , General Guidelines for Clinical Evaluation of Antimicrobial Agents 5) , and Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy). 1) 
4) Dosage and administrations
The basis for dosage and administrations will be described by referring to Breakpoint for Septicemia and Respiratory Tract Infections (Japanese Society of Chemotherapy) 6) , and by considering the results of non-clinical trials and previous clinical trials.
5) Administration period
The basis for the period of administration will be described in accordance with Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy). 1) 6) Completion and discontinuation criteria The basis for the completion and discontinuation crite-ria will be described in accordance with the characteristics of the clinical trial.
7) Pretreatment and meals
The basis for pretreatment and conditions regarding meals will be described in accordance with the characteristics of the clinical trial.
8) Prohibited concomitant drugs/therapies
The basis for the prohibition of concomitant drugs/ therapies will be described in accordance with the characteristics of the clinical trial. 9) Concomitant drugs/therapies that need careful attention The basis of the need for careful attention for certain concomitant drugs/therapies will be described in accordance with the characteristics of the clinical trial.
10) Observation and test parameters
The basis for observation and test parameters will be described by referring to Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy). 1) 11) Time of observation and tests The basis for the times that are set for observation and tests will be described by referring to Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy). 1) 12) Treatment following the completion or discontinuation of administration of the investigational product [Example] This was established in order to collect information on the efficacy of the investigational product from the treatments that were conducted following the completion or discontinuation of administration of the investigational product. 13) Follow-up for subjects who did not continue visiting [Example] This was established in order to ensure the safety of subjects who did not continue visiting. 14) Assessment related to demographics
The basis for severity criteria for infectious diseases, primary diseases and complications, which are related to the inclusion/exclusion criteria, will be described by referring to Clinical Evaluation Methods for New Antimicrobial Agents for the Treatment of Respiratory Tract Infections (Japanese Society of Chemotherapy). 1) 15) Primary efficacy and safety variables The basis for variables that are thought to be necessary in order to achieve the objective of the clinical trial will be described.
16) Secondary efficacy and safety variables
The basis for variables that are thought to be necessary to explore/confirm the characteristics of the investigational product and achieve the objective of the clinical trial will be described. 17) Entries that ensure the safety of subjects
The basis for the entries that ensure the safety of subjects will be described by referring the results of safety issues in non-clinical trials and previous clinical trials.
18) Case population
The basis for the setting the number of cases in order to achieve the objective of the clinical trial should be described using statistical and clinical reasons. The basis for the predicted value (expected efficacy rate etc.) will be described.
